^
CANCER:

Gastrointestinal Cancer

15h
Effects of circuit, interval-based exercise on insulin resistance and metabolic biomarkers in sedentary and obese cancer survivors (MASCC-ISOO 2022)
Compared to usual care, exercise improved insulin resistance (between group mean difference, -9.4; p=0.001), adiponectin (8.4; p=0.003), and leptin (-11.7; p=0.001). Conclusions A 16-week circuit, interval-based exercise intervention was effective in improving metabolic biomarkers including insulin resistance, adiponectin, and leptin among sedentary and obese cancer survivors.
LEP (Leptin)
15h
Loss Of Skeletal Muscle And Adiposity Measured By Computed Tomography Predicts Survival In Advanced Biliary Tract Cancer Patients (MASCC-ISOO 2022)
This classification was independent factor in multi-variate analysis along with, carcinoembryonic antigen, neutrophil-to-lymphocyte ratio, white blood cell count, platelet, and cholesterol (HR 1.271, 95% CI 1.126-1.435). Conclusions Sarcopenia, MA, and adiposity predict mortality in advanced BTC patients and can be utilized as surrogate markers for prognosis.
Clinical
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
23h
MicroRNA-148a Inhibits Hepatocellular Carcinoma Cell Growth via Epithelial-to-Mesenchymal Transition and PI3K/AKT Signaling Pathways by Targeting Death Receptor-5. (PubMed, Appl Biochem Biotechnol)
In conclusion, data in the current study indicate that miR-148a inhibits HCC cells growth via downregulation of EMT and PI3K/AKT signaling pathways by targeting death receptor. These data suggest that miR-148a may serve as a therapeutic target for HCC cancer therapy in the future.
Journal
|
MIR148A (MicroRNA 148a) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
23h
A case of invasive intraductal papillary mucinous carcinoma arising from jejunal heterotopic pancreas (PubMed, Nihon Shokakibyo Gakkai Zasshi)
Histopathology revealed an invasive IPMC arising from a heterotopic pancreas (Heinrich type II) and chemotherapy with gemcitabine and nab-paclitaxel was initiated. There have only been three cases of invasive IPMC from a heterotopic pancreas reported, and this is the first one to include chemotherapeutic treatment of distant metastasis.
Journal
|
CA 19-9 (Cancer antigen 19-9)
|
gemcitabine • albumin-bound paclitaxel
23h
Clinicopathological festures and outcome of combined hepatocellular-cholangiocarcinoma (PubMed, Zhonghua Yi Xue Za Zhi)
The definite diagnosis depends on histopathological morphology and immunohistochemical markers. Nestin may be as a prognosis factor, and surgical treatment is preferably liver resection.
Retrospective data • Journal
|
NES (Nestin)
23h
A natural mutator allele shapes mutation spectrum variation in mice. (PubMed, Nature)
The B and D quantitative trait locus haplotypes encode different alleles of Mutyh, a DNA repair gene that underlies the heritable cancer predisposition syndrome that causes colorectal tumors with a high SBS18 mutation load. Both B and D Mutyh alleles are present in wild populations of Mus musculus domesticus, providing evidence that common genetic variation modulates germline mutagenesis in a model mammalian species.
Preclinical • Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • MUTYH (MutY homolog)
23h
Accuracy evaluation of combining gastroscopy, multi-slice spiral CT, Her-2, and tumor markers in gastric cancer staging diagnosis. (PubMed, World J Surg Oncol)
The combined diagnosis of gastroscopy, MSCT, immunohistochemical marker Her-2, and tumor markers CEA, CA199, CA724, and CA242 can more accurately determine the clinical staging and lesion invasion depth of patients with gastric cancer and can significantly improve the sensitivity of diagnosis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CA 19-9 (Cancer antigen 19-9)
|
HER-2 expression
23h
β-Patchoulene represses hypoxia-induced proliferation and epithelial-mesenchymal transition of liver cancer cells. (PubMed, Bioengineered)
Further mechanism studies displayed that β-PAE inactivated the NF-κB/HIF-1α pathway, and HIF-1α activation significantly reversed the β-PAE-mediated tumor inhibition. β-PAE repressed the proliferation and EMT of hypoxia-induced HCC cells by choking the NF-κB/HIF-1α pathway, suggesting that β-PAE was a potential drug for HCC treatment.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • HIF1A expression
23h
Far upstream element -binding protein 1 (FUBP1) participates in the malignant process and glycolysis of colon cancer cells by combining with c-Myc. (PubMed, Bioengineered)
c-Myc overexpression reversed the inhibitory effects of FUBP1 knockdown on the ability of HCT116 cells to proliferate, migrate, invade and glycolysis. The results indicated that FUBP1 could participate in the deterioration process of colon cancer cells by combining with c-Myc, and it has clinical significance for understanding the key role of FUBP1 in tumor genesis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC overexpression • MYC expression
23h
The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells. (PubMed, Sci Rep)
We further found that the forkhead box protein A2 (FOXA2) binds to E2 and the promoter; suppression of FOXA2 expression resulted in MALAT1 up-regulation and increased cell proliferation. These results suggest that the inhibition of MALAT1 may improve the effect of BET inhibitors as an anti-cancer therapy and that FOXA2 would be a suitable target for that approach.
Journal
|
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • BRD4 (Bromodomain Containing 4) • FOXA2 (Forkhead Box A2)
|
JQ-1
23h
Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study. (PubMed, BMC Gastroenterol)
mSEPT9 demonstrated moderate diagnostic value in CRC detection, which was similar to the FIT but superior to the CEA, CA125 and CA199. Combination of mSEPT9 and FIT further improved diagnostic sensitivity in CRC.
Clinical • Journal
|
MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9) • SEPTIN9 (Septin 9)
23h
Assessing surveillance utilization and value in commercially insured patients with colorectal cancer. (PubMed, Am J Manag Care)
Higher intensity of surveillance, beyond what is recommended by guidelines, may lead to earlier recurrence detection and subsequent treatment, but this is associated with significantly higher direct medical costs.
Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
23h
Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. (PubMed, Theranostics)
The overexpression of Oct4 and c-Myc also generated secretomes that inhibited the development of bone-resorbing osteoclasts. In analogous to cell competition in which Myc-overexpressing cells in Drosophila and mouse embryos remove neighboring cells with a lower level of Myc, this study presented the possibility of eliminating tumor cells by the secretory proteomes derived from Myc/Oc4-overexpressing iTSCs.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD44 • KLF4 (Kruppel-like factor 4) • POU5F1 (POU Class 5 Homeobox 1) • SOX2 • ENO1 (Enolase 1) • VCL (Vinculin) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
|
MYC overexpression • MYC expression • POU5F1 expression
23h
mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma. (PubMed, Theranostics)
Furthermore, the paraspeckle-mediated mechanism is important for the anticancer action of US FDA-approved drugs rapamycin/temsirolimus. These findings reveal a molecular mechanism by which mTOR promotes the 'Warburg Effect', which is important for the metabolism and development of HCC, and anticancer response of mTOR-targeted therapy.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
Torisel (temsirolimus) • sirolimus
23h
Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. (PubMed, Theranostics)
Further, PEG-MP9-aPDL1 exhibited prominent immunotherapeutic efficacy in a CRC mouse model characterized by tumor infiltration of CD8+ T cells and induction of cytotoxic lymphocytes (CTLs) in the spleens. Our findings suggest that PEG-MP9-aPDL1 is an all-in-one platform for oncolytic immunotherapy and immune checkpoint blockade (ICB).
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MMP2 (Matrix metallopeptidase 2)
23h
Enhanced ASGR2 by microplastic exposure leads to resistance to therapy in gastric cancer. (PubMed, Theranostics)
Further, PS-induced multidrug resistance to bortezomib, paclitaxel, gefitinib, lapatinib, and trastuzumab was observed in the NCI-N87 mouse model due to upregulated CD44 expression. We demonstrated that ASGR2 enhanced cancer hallmarks on PS exposure and induced resistance to chemo- and monoclonal antibody-therapy. Our preclinical findings may provide an incentive for further epidemiological studies on the role of MP exposure and its association with gastric cancer.
Journal
|
CDH1 (Cadherin 1) • CD44 • CDH2 (Cadherin 2)
|
CD44 expression • CDH1 expression
|
Herceptin (trastuzumab) • gefitinib • paclitaxel • lapatinib • bortezomib
24h
New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. (PubMed, J Enzyme Inhib Med Chem)
Compounds 4a-j displayed ICs ranged from 2.53-8.67 µM, 8.67-62.47 µM, and 4.19-24.37 µM for HCT116, HT29, and Caco-2 cells; respectively, whereas the doxorubicin, showed IC values of 1.22, 0.88, and 4.15 µM. They increased the protein expression level of γH2AX, indicating DNA damage, and arrested HCT116 in G2/M phase, possibly through the ATR/CHK1/Cdc25C pathway. Thus, the novel ciprofloxacin hybrids could be exploited as potential leads for further investigation as novel anticancer medicines to fight colorectal carcinoma.
Journal
|
CDC25C (Cell Division Cycle 25C) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
doxorubicin hydrochloride • ciprofloxacin oral
24h
Downregulated Reprimo by LINC00467 participates in the growth and metastasis of gastric cancer. (PubMed, Bioengineered)
Knockdown of LINC00467 reduced tumorigenesis and metastasis of GC cells in vivo. LINC00467 might exert oncogenic effects in GC via Reprimo downregulation by recruiting DNMT1.
Journal
|
DNMT1 (DNA methyltransferase 1)
24h
Nanomolar EP4 receptor potency and expression of eicosanoid-related enzymes in normal appearing colonic mucosa from patients with colorectal neoplasia. (PubMed, BMC Gastroenterol)
In conclusion, normal appearing colonic mucosa from CRN patients demonstrates deviating expression in eicosanoid pathways, which might indicate a likely predisposition for early CRN development and furthermore that PGE potently activates high affinity EP4 receptor subtypes, supporting relevance of testing EP4 antagonists in colorectal neoplasia management.
Journal
|
ALOX15 (Arachidonate 15-Lipoxygenase)
24h
Circular_0086414 induces SPARC like 1 (SPARCL1) production to inhibit esophageal cancer cell proliferation, invasion and glycolysis and induce cell apoptosis by sponging miR-1290. (PubMed, Bioengineered)
Further, circ_0086414 stimulated SPARCL1 production by negatively regulating miR-1290. Thus, circ_0086414 inhibited EC cell malignancy through the miR-1290/SPARCL1 pathway, providing a reliable target for the therapy of EC.
Journal
|
CDH1 (Cadherin 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • CDH2 (Cadherin 2) • MIR1290 (MicroRNA 1290)
|
CDH1 expression
24h
Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan. (PubMed, BMC Cancer)
Among a panel of inflammation and nutritional markers, the GNRI exhibited the best performance as a prognostic factor after curative gastrectomy in elderly patients with gastric cancer, indicating its utility as a simple and promising index for predicting OS and DSS in these patients.
Clinical • Retrospective data • Journal
|
CRP (C-reactive protein)
24h
A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma. (PubMed, Bioengineered)
Overexpression of CFHR3 in HCC cells under hypoxia reversed the stimulatory effects of hypoxia and suppressed cell proliferation and metastasis in vivo. In conclusion, we identified a novel hypoxia-driven gene signature (CFHR3, EGLN3, and CHGA) for reliable prognostic prediction of HCC, and demonstrated that overexpression of CFHR3 may be a potential strategy to overcome hypoxia and treat HCC.
Journal • Gene Signature
|
CHGA (Chromogranin A)
24h
Role of CD68 in tumor immunity and prognosis prediction in pan-cancer. (PubMed, Sci Rep)
The clinical prognosis and immune infiltration of high expression levels of CD68 differ across tumor types. Inhibiting CD68-dependent signaling could be a promising therapeutic strategy for immunotherapy in many tumor types.
Journal • IO biomarker • Pan tumor
|
CD68 (CD68 Molecule)
24h
Helicobacter pylori Infection Mediates Inflammation and Tumorigenesis-Associated Genes Through miR-155-5p: An Integrative Omics and Bioinformatics-Based Investigation. (PubMed, Curr Microbiol)
Based on the specific patterns of expression in gastritis and cancer, CD9, MST1R, and ADAM10 were candidates for the most probable targets of miR-155-5p. Although the focus of this study is primarily on bioinformatics, we think that our findings should be experimentally validated before they can be used as potential therapeutic and diagnostic tools.
Journal
|
MIR155 (MicroRNA 155) • CD9 • ADAM10 (ADAM Metallopeptidase Domain 10)
|
miR-155 expression
24h
Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response. (PubMed, PLoS One)
Lowest cell proliferation was achieved with the concomitant use of genomic DNA, HGFR inhibitor, and chloroquine, when the proliferation stimulating effect of STAT3 overexpression could be outweighed by the inhibitory effect of LC3B, indicating the putative involvement of HGFR-mTOR-ULK1 molecular cascade in HGFR inhibitor-mediated autophagy...The observed ultrastructural changes also support the context-dependent role of HGFR inhibition and autophagy on cell survival and proliferation. Further investigation of the influence of the studied signaling pathways and cellular processes can provide a basis for novel, individualized anti-cancer therapies.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • TLR9 (Toll Like Receptor 9)
|
STAT3 expression • MYD88 overexpression
|
chloroquine phosphate
24h
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. (PubMed, Cancer Treat Res)
Examples to be reviewed include TLR agonists, STING agonists, RIG-I agonists, and attenuated or engineered viruses and bacterium. I also review common key requirements for effective in situ immune activation, discuss differences between various strategies inclusive of mechanisms that may ultimately limit or preclude antitumor efficacy, and provide a summary of relevant clinical data.
Journal
|
CD8 (cluster of differentiation 8)
24h
Influence of 6-shogaol potentiated on 5-fluorouracil treatment of liver cancer by promoting apoptosis and cell cycle arrest by regulating AKT/mTOR/MRP1 signalling. (PubMed, Chin J Nat Med)
Moreover, our results showed that 6-shogaol-5-FU combination treatment notably inhibited tumour growth in vivo. In summary, our data demonstrated that 6-shogaol contributed to the curative outcome of 5-FU in liver cancer by inhibiting the AKT/mTOR/MRP1 signalling pathway.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MSH3 (MutS Homolog 3)
|
5-fluorouracil
24h
Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes. (PubMed, NPJ Syst Biol Appl)
KO-specific changes in rhythmic properties of known spliced variants of these genes (e.g. FGFR2 IIIb/FGFR2 IIIc) correlated with epithelial-mesenchymal-transition signalling. Altogether, our bioinformatic analysis highlights a role for the circadian clock in the regulation of AS, and reveals a potential impact of clock disruption in aberrant splicing in cancer hallmark genes.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD44 • PER2 (Period Circadian Regulator 2) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
24h
Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma. (PubMed, PLoS One)
Thus many, if not most, HCC patients who are "non-cirrhotic" may in fact have regressed cirrhosis. This finding reinforces that patients with regressed cirrhosis continue to be at high risk for HCC.
Journal
|
CD34 (CD34 molecule)
24h
The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer. (PubMed, Int J Oncol)
In addition, continuous treatment with R848 increased the proportion of DCs, NK and CD8 T cells, and reduced that of Foxp3 regulatory T cells in the tumor microenvironment. These findings supported the use of R848 treatment for lung cancer via TLR7 targeting and provided insight into the underlying therapeutic mechanism.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FOXP3 (Forkhead Box P3)
24h
Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. (PubMed, Clin Exp Immunol)
In conclusion, our study provides a comprehensive blueprint of the immune microenvironment of HER2-positive gastric tumors. This analysis highlights the importance of considering the tumor microenvironment when assessing response to immune checkpoint inhibitors.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression • HER-2 positive • HER-2 overexpression • PD-1 expression • LAG3 expression • CTLA4 expression • HER-2-H
24h
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. (PubMed, Nat Commun)
Furthermore, PPARδ ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARδ ligand) in mutant KRAS (KRAS) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC. This PPARδ activation induces KRAS pancreatic epithelial cells to secrete CCL2, which recruits immunosuppressive macrophages and myeloid-derived suppressor cells into pancreas via the CCL2/CCR2 axis to orchestrate an immunosuppressive tumor microenvironment and subsequently drive PanIN progression to PDAC. Our data identify PPARδ signaling as a potential molecular target to prevent PDAC development in subjects harboring PanINs.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CCL2 (Chemokine (C-C motif) ligand 2)
|
KRAS mutation
|
endurobol (GW501516)
24h
Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells. (PubMed, Sci Rep)
Survival analysis revealed the significant prognostic value for some of the hub genes, TFs, and lncRNAs. The results of the present study can extend the vision on the molecular mechanisms involved in KRAS-driven CRC pathogenesis.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MIR23b (MicroRNA 23b)
|
KRAS mutation • KRAS wild-type
24h
Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up. (PubMed, BMC Gastroenterol)
This study shows that HER2 overexpression is significantly associated with tumor recurrence in pN0 EGC. Hence, Her2 testing at diagnosis is important and differential treatment and/or follow up strategies for patients with Her2 overexpression may merit future study.
Observational data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
24h
Diagnostic and prognostic values of pyroptosis-related genes for the hepatocellular carcinoma. (PubMed, BMC Bioinformatics)
In a word, BAK1, BAX, CHMP2A, CHMP4C, CHMP6, GSDMC, GSDMD, and the pyroptosis-related risk model could be used to diagnose the HCC, and the risk score also resulted as an independent risk factor for the HCC prognosis.
Journal
|
TP53 (Tumor protein P53) • GPX4 (Glutathione Peroxidase 4) • BAK1 (BCL2 Antagonist/Killer 1)
24h
Preoperative diagnosis and prediction of microvascular invasion in hepatocellularcarcinoma by ultrasound elastography. (PubMed, BMC Med Imaging)
The hardness of tumor-adjacent tissues, maximum tumor diameter, and the preoperative prediction model predict the occurrence of MVI in HCC patients.
Retrospective data • Journal
|
AFP (Alpha-fetoprotein)
24h
VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. (PubMed, J Transl Med)
Collectively, these findings demonstrate that VCP is a potential prognostic biomarker in HCC and exhibits oncogenic roles via PI3K/AKT/mTOR pathway activation. HMGB1 played an essential role in VCP-mediated HCC progression, indicating that VCP and HMGB1 are potential therapeutic targets in human HCC.
Journal
|
HMGB1 (High Mobility Group Box 1)
24h
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. (PubMed, J Transl Med)
Colorectal patient-derived scaffold can decode clinically relevant tumor microenvironmental influence of 5-fluorouracil treatment effects opening up for optimized precision medicine in colorectal cancer treatment.
Journal
|
POU5F1 (POU Class 5 Homeobox 1)
|
5-fluorouracil
24h
The interaction between long non-coding RNA LINC01564 and POU2F1 promotes the proliferation and metastasis of gastric cancer. (PubMed, J Transl Med)
Taken together, our results indicate that the interaction between LINC01564 and POU2F1 promotes the proliferation, migration and invasion of GC cells.
Journal
|
LINC01564 (Long Intergenic Non-Protein Coding RNA 1564)
24h
Single-cell landscape of immunocytes in patients with extrahepatic cholangiocarcinoma. (PubMed, J Transl Med)
In a word, our study illuminated the components of the TME and revealed potential cellular interactions at the individual cellular level in ECCA, we aimed to provide a new perspective for further immunological studies and immunotherapy of ECCA.
Journal
|
CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CD4 (CD4 Molecule) • CD27 • SDC1 (Syndecan 1) • CCR8 (C-C Motif Chemokine Receptor 8)
24h
A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression. (PubMed, J Exp Clin Cancer Res)
Our work identified a positive feedback loop governing cancer cells and macrophage in GC that contributed to tumor progression and patient outcome.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • JAK1 (Janus Kinase 1) • IL10 (Interleukin 10) • CXCR1 (Chemokine (C-X-C motif) receptor 1)
|
CXCL8 expression
24h
The P2X7 Receptor Promotes Colorectal Inflammation and Tumorigenesis by Modulating Gut Microbiota and the Inflammasome. (PubMed, Int J Mol Sci)
Microbial changes were observed in the P2X7R and P2X7R-induced mice, partially reversed by the A740003 treatment. Regulatory mechanisms activated downstream of the P2X7R in combination with signals from a dysbiotic microbiota result in the activation of intracellular signaling pathways and the inflammasome, amplifying the inflammatory response and promoting CA-CRC development.
Journal
|
NLRP3 (NLR Family Pyrin Domain Containing 3)
24h
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia. (PubMed, Int J Mol Sci)
This paper presents (1) previous studies regarding the role of KIT mutations in AML, (2) the data in AML with KIT mutations from the HM-SCREEN-Japan-01 study, a genome profiling study for patients newly diagnosed with AML who are unsuitable for the standard first-line treatment (unfit) or have relapsed/refractory AML, and (3) new therapies targeting KIT mutations, such as tyrosine kinase inhibitors and heat shock protein 90 inhibitors. In this era when genome profiling via next-generation sequencing is becoming more common, KIT mutations are attractive novel molecular targets in AML.
Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT mutation
24h
Notch-Sox9 Axis Mediates Hepatocyte Dedifferentiation in Kras-Induced Zebrafish Hepatocellular Carcinoma. (PubMed, Int J Mol Sci)
Furthermore, we found that inhibition of the Notch signaling pathway or deficiency of sox9b both prevented hepatocyte dedifferentiation following hepatocellular carcinoma induction, reducing cancer metastasis and improving survival. In conclusion, we found that hepatocytes undergo dedifferentiation after hepatocarcinogenesis, a process that requires Notch signaling and likewise the activation of Sox9.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • SOX9 (SRY-Box Transcription Factor 9)
24h
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. (PubMed, Int J Mol Sci)
Thus, DDR alterations are suitable targets for drug development and to improve the outcome in both pancreatic and prostate cancer patients. Importantly, this will increase the detection of germline pathogenic variants, thereby patient referral to genetic counseling.
Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
24h
Leptin Signaling in Obesity and Colorectal Cancer. (PubMed, Int J Mol Sci)
This review summarizes the current knowledge on leptin genetics and its potential relationship with the main pathogenic pathways of obesity and CRC, in an attempt to understand the molecular mechanisms of these associations, in the context of inconsistent and contradictory data. The understanding of these mechanisms linking obesity and CRC could help to develop novel therapeutic targets and prevention strategies, resulting in a better prognosis and management of these diseases.
Review • Journal
|
LEP (Leptin)
24h
Evidence That β1-Integrin Is Required for the Anti-Viability and Anti-Proliferative Effect of Resveratrol in CRC Cells. (PubMed, Int J Mol Sci)
Similarly, resveratrol-blocked TME-induced p65-NF-kB and its promoted gene markers linked to proliferation (cyclin D1), invasion (focal adhesion kinase, FAK), or apoptosis (caspase-3), were largely abrogated by anti-β1-integrin or RGD peptide, suggesting that β1-integrin is a potential transmission pathway for resveratrol/integrin down-stream signaling in CRC cells. The current results highlight, for the first time, the important gateway role of β1-integrins as signal carriers for resveratrol on the surfaces of HCT116 and SW480 cells, and their functional cooperation for the modulatory effects of resveratrol on TME-promoted tumorigenesis.
Journal
|
CCND1 (Cyclin D1) • CASP3 (Caspase 3) • RELA (RELA Proto-Oncogene)
24h
Long Non-Coding LEF1-AS1 Sponge miR-5100 Regulates Apoptosis and Autophagy in Gastric Cancer Cells via the miR-5100/DEK/AMPK-mTOR Axis. (PubMed, Int J Mol Sci)
Studies have shown that miR-5100 acts by targeting the 3'UTR of DEK, and LEF1-AS1 regulates the expression of miR-5100 by sponging with mIR-5100. In conclusion, our results found that LEF1-AS1 and miR-5100 sponge function, and the miR-5100/DEK/AMPK/mTOR axis regulates autophagy and apoptosis in gastric cancer cells.
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • MIR5100 (MicroRNA 5100)
24h
Modulation of Mismatch Repair and the SOCS1/p53 Axis by microRNA-155 in the Colon of Patients with Primary Sclerosing Cholangitis. (PubMed, Int J Mol Sci)
Thus, under different conditions, miR-155 is involved in either neoplastic transformation in the ascending colon or chronic colitis in the sigmoid colon of patients with PSC. New insight into local modulation of microRNAs, that may alter the course of the disease, could be used for further research on potential therapeutic applications.
Journal • Mismatch repair • MSi-H Biomarker
|
MSI (Microsatellite instability) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR155 (MicroRNA 155) • SOCS1 (Suppressor Of Cytokine Signaling 1) • IL17A (Interleukin 17A) • FOXP3 (Forkhead Box P3)
|
MSI-H/dMMR • STAT3 expression • miR-155 overexpression
24h
Deoxyelephantopin Induces Apoptosis and Enhances Chemosensitivity of Colon Cancer via miR-205/Bcl2 Axis. (PubMed, Int J Mol Sci)
To further examine the potential value of the drug, we evaluated the combinative effects of DET and 5-Fluorouracil (5FU) through Jin's formula and revealed that DET acted synergistically with 5FU, resulting in enhancing the chemotherapeutic sensitivity of CC to 5FU. Our results consolidate DET as a potent drug for the treatment of CC when it is used alone or combined with 5FU, and elucidate the importance of the miR-205-Bcl2 axis in DET treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MIR205 (MicroRNA 205)
|
BCL2 expression
|
5-fluorouracil
24h
Radiosensitization to γ-Ray by Functional Inhibition of APOBEC3G. (PubMed, Int J Mol Sci)
Using a xenograft model of A549 in mice, enhanced radiosensitivity by a combination of X-ray irradiation and APOBEC3G knockdown was observed. These results suggest that the functional inhibition of APOBEC3G sensitizes cancer cells to radiation by attenuating the activation of the DNA repair pathway, suggesting that APOBEC3G could be useful as a target for the radiosensitization of cancer therapy.
Journal
|
APOB (Apolipoprotein B)
24h
Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol. (PubMed, Int J Mol Sci)
Consistent with ATD, the administration of S3I201 (STAT 3 inhibitor) reduced the expression of Bcl-2/Bcl-xL, cyclin D1, mutp53, and MVK. These results demonstrated ATD's selectivity against mutp53 hepatoma cells involving the downregulation of mutp53 and inactivation of STAT3.
Journal • PARP Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CDK2 (Cyclin-dependent kinase 2) • TGFB1 (Transforming Growth Factor Beta 1) • ANXA5 (Annexin A5)
|
TP53 mutation • TP53 wild-type • BCL2 expression • CCND1 expression • STAT3 expression • TP53 expression • BAX expression • TP53 Y220C • CDK2 expression
|
GLG-302
24h
Tumor Infiltration with CD20CD73 B Cells Correlates with Better Outcome in Colorectal Cancer. (PubMed, Int J Mol Sci)
Finally, neoadjuvant therapy correlated with reduced CD73 B-cell numbers and CD73 expression on B-cells in the CRC tumors. As promising new immune therapies are being developed, the role of CD73 B-cells and their subsets in the development of colorectal cancer should be further explored to find new therapeutic options.
Journal • IO biomarker
|
NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
24h
Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells. (PubMed, Int J Mol Sci)
Sulforaphane suppresses the nicotine-induced MMP-9 by inhibiting ROS-mediated MAPK (p38 MAPK, Erk1/2)/AP-1 and ROS-mediated NF-κB signaling axes, which in turn inhibit cell invasion in human gastric cancer AGS cells. Therefore, the current study provides valuable evidence for developing sulforaphane as a new anti-invasion strategy for human gastric cancer therapy.
Journal
|
MMP9 (Matrix metallopeptidase 9)
24h
Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model. (PubMed, Int J Mol Sci)
In conclusion, we show that Ido1 deficiency aggravates atherosclerosis, but not liver disease, in a newly established NASH and atherosclerosis comorbidity model. Our data indicate that the overexpression of TDO2 is an important mechanism that helps in balancing the kynurenine pathway and inflammation in the liver, but not in the artery wall, which likely determined disease outcome in these two target tissues.
Journal • IO biomarker
|
IDO1 (Indoleamine 2,3-dioxygenase 1) • GLI2 (GLI Family Zinc Finger 2) • TDO2 (Tryptophan 2,3-Dioxygenase) • APOE (Apolipoprotein E)
|
TDO2 overexpression
24h
Expression of Autophagic and Inflammatory Markers in Normal Mucosa of Individuals with Colorectal Adenomas: A Cross Sectional Study among Italian Outpatients Undergoing Colonoscopy. (PubMed, Int J Mol Sci)
Presence of adenomas correlated with cholesterol (total and LDL) levels, IL-6 levels, and MAPLC3 tissue expression, especially in the right colon. In conclusion, serum IL-6 amount and autophagic markers could be good predictors of the presence of colorectal adenomas.
Observational data • Journal
|
IL6 (Interleukin 6)
|
IL6 expression
24h
Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. (PubMed, Int J Mol Sci)
These observations were partially induced by the downregulation of microRNA122-5p (miR-122-5p) and occurred particularly in the Kupffer cells. Our results suggest that the activation of glycolysis in Kupffer cells during NASH was partially induced by the upregulation of PKM2 via miR-122-5p suppression.
Preclinical • Journal
|
MIR122 (MicroRNA 122) • PKM (Pyruvate Kinase M1/2)
24h
Granzymes-Their Role in Colorectal Cancer. (PubMed, Int J Mol Sci)
This paper summarises the role of GZMs in CRC pathogenesis through their involvement in the inflammatory process. Therefore, it seems that GZMs could become the focus of research into new CRC biomarkers.
Review • Journal
|
GZMA (Granzyme A)
24h
Plant Alkaloid Tetrandrine Is a Nuclear Receptor 4A1 Antagonist and Inhibits Panc-1 Cell Growth In Vitro and In Vivo. (PubMed, Int J Mol Sci)
Furthermore, at a dose of 25 mg/kg/day, TTD reduced tumor growth in an athymic nude mouse xenograft model bearing Panc-1 cells. These data show that TTD is an NR4A1 antagonist and that modulation of the NR4A1-mediated pro-survival pathways is involved in the antitumor effects of TTD.
Preclinical • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
CBT-1 (tetrandrine)
24h
Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy. (PubMed, Int J Mol Sci)
Captopril treatment reduced populations of myeloid-derived suppressor cells (MDSCs) (CD11bLy6C&nbsp;p < 0.05, CD11bLy6C&nbsp;p < 0.01) and increased PD-1 expression on infiltrating hepatic tissue-resident memory (T)-like CD8 (p < 0.001) and double-negative (CD4CD8; p < 0.001) T cells; (4) RASi reduced CRLM growth in the regenerating liver and altered immune cell composition by reducing populations of immunosuppressive MDSCs and boosting populations of PD-1 hepatic Ts. Thus, RASi should be explored as an adjunct therapy for patients undergoing partial hepatectomy for CRLM.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-1 expression
|
captopril
24h
P-Cadherin Regulates Intestinal Epithelial Cell Migration and Mucosal Repair, but Is Dispensable for Colitis Associated Colon Cancer. (PubMed, Cells)
Our findings highlight P-cadherin as a negative regulator of IEC motility in vitro and mucosal repair in vivo. In contrast, this protein is dispensable for IEC proliferation and CAC development.
Journal
|
RAC1 (Rac Family Small GTPase 1) • CDH3 (Cadherin 3)
24h
Obesity-Associated Cancers: Evidence from Studies in Mouse Models. (PubMed, Cells)
These models include monogenic models of obesity (e.g., ob/ob and db/db mice) and genetically modified mouse models of human cancers (e.g., Kras-driven pancreatic cancer, Apc-mutated colorectal cancer, and Her2/neu-overexpressing breast cancer). The experimental results obtained using these mouse models revealed strong evidence of a link between obesity and cancer and suggested their underlying mechanisms.
Preclinical • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • APC (APC Regulator Of WNT Signaling Pathway)
|
HER-2 overexpression • HER-2 mutation • APC mutation
24h
Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. (PubMed, Cells)
NLRP3 inflammasome (nucleotide-binding oligomerization domain-like receptor protein 3) is a multiprotein complex that activates caspase 1 and the release of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and interleukin-18 (IL-18), and contributes to inflammatory pyroptotic cell death. The present review, which is part of the issue "Mitochondria in Liver Pathobiology", provides an overview of the role of mitochondrial dysfunction and NLRP3 activation in ASH and NASH.
Review • Journal
|
NLRC5 (NLR Family CARD Domain Containing 5) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
24h
Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. (PubMed, Cells)
Many of these observations were confirmed by in vivo angiogenesis models, which showed that crocin significantly reduced the progression of tumour growth. Collectively, these finding suggest that crocin inhibits angiogenesis and colorectal cancer cell metastasis by targeting NF-kB and blocking TNF-α/NF-κB/VEGF pathways.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
24h
LINC00152 Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma. (PubMed, Cells)
Functional assays demonstrated that KLC2 promoted cell proliferation, clonogenicity and migration in vitro. The LINC00152-miR-143a-3p-KLC2 axis may represent a therapeutic target in human HCC.
Journal
|
Let-7c (MicroRNA Let-7c) • MIR143 (MicroRNA 143) • MIR23A (MicroRNA 23a) • MIR125A (MicroRNA 125a) • MIR195 (MicroRNA 195)
24h
LINC00665: An Emerging Biomarker for Cancer Diagnostics and Therapeutics. (PubMed, Cells)
LINC00665 is closely associated with the effects of anticancer drugs, including gefitinib and cisplatin in non-small cell lung cancer, gemcitabine in cholangiocarcinoma, and cisplatin-paclitaxel in breast cancer. This work systematically summarizes the diagnostic and prognostic values of LINC00665 in various tumors, and comprehensively analyzes the molecular regulatory mechanism related to LINC00665, which is expected to provide clear guidance for future research.
Review • Journal
|
CIP2A (Cellular Inhibitor Of PP2A) • TGFB1 (Transforming Growth Factor Beta 1) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665)
|
cisplatin • gefitinib • paclitaxel • gemcitabine
1d
Enhanced Growth Inhibition and Apoptosis Induction in Human Colon Carcinoma HT-29 Cells of Soluble Longan Polysaccharides with a Covalent Chemical Selenylation. (PubMed, Nutrients)
Collectively, both SeLP1 and SeLP2 showed higher activities than LP in HT-29 cells, while SeLP2 was consistently more active than SeLP1 in exerting these assessed anti-cancer effects on the cells. In conclusion, this chemical selenylation covalently introduced Se into the polysaccharide molecules and caused an enhancement in their anti-cancer functions in the cells, while higher selenylation extent was beneficial to the activity enhancement of the selenylated products.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
1d
Lactiplantibacillus plantarum-12 Alleviates Inflammation and Colon Cancer Symptoms in AOM/DSS-Treated Mice through Modulating the Intestinal Microbiome and Metabolome. (PubMed, Nutrients)
Taken together, L. plantarum-12 oral administration could ameliorate the colon cancer burden and inflammation of AOM-DSS-treated C57BL/6 mice through regulating the intestinal microbiota, manipulating fecal metabolites, enhancing colon barrier function, and inhibiting NF-κB signaling. These results suggest that L. plantarum-12 might be an excellent probiotic candidate for the prevention of colon cancer.
Preclinical • Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • PCNA (Proliferating cell nuclear antigen)
1d
The Inhibition of Gastric Cancer Cells' Progression by 23,24-Dihydrocucurbitacin E through Disruption of the Ras/Raf/ERK/MMP9 Signaling Pathway. (PubMed, Molecules)
Collectively, our study demonstrated that DHCE suppressed gastric cancer cells' proliferation, migration, and invasion through targeting ERK2 and disrupting the Ras/Raf/ERK/MMP9 signaling pathway. These properties make DHCE a promising candidate drug for the further design and development of novel and effective Ras/Raf/ERK/MMP9 pathway inhibitors for treating gastric cancer.
Journal
|
MAPK1 (Mitogen-activated protein kinase 1) • MMP9 (Matrix metallopeptidase 9)
1d
Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells. (PubMed, Molecules)
Further studies showed that the treatment of shikonin sensitized pancreatic cancer cells to chemotherapeutic drugs. These results suggest that shikonin, a potential natural inhibitor targeting PAK1 kinase, has promising potent applications in the treatment of pancreatic cancer and chemotherapy sensitization.
Journal
|
PAK1 (p21 (RAC1) activated kinase 1)
1d
Tentatively Identified (UPLC/T-TOF-MS/MS) Compounds in the Extract of Saussurea costus Roots Exhibit In Vivo Hepatoprotection via Modulation of HNF-1α, Sirtuin-1, C/ebpα, miRNA-34a and miRNA-223. (PubMed, Molecules)
Paracetamol toxicity caused a significant increase in plasma caspase 2, cytokeratin 18 (CK18), liver tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), miRNA-34a, and miRNA-223, as well as a significant decrease in liver catalase (CAT) activity and in the levels of liver nuclear factor 1α (HNF-1α), sirtuin-1, and C/ebpα...The histological examination showed a significant normalization in rats pretreated with MESC. Our findings showed that Saussurea costus may exert a potent hepatoprotective activity through the modulation of the expression of cellular cytokines, miRNA-34a, and miRNA-223.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR34A (MicroRNA 34a-5p) • SIRT1 (Sirtuin 1) • CAT (Catalase)
|
paracetamol
1d
Gastric Cancer Pre-Stage Detection and Early Diagnosis of Gastritis Using Serum Protein Signatures. (PubMed, Molecules)
Two protein panels were suggested for the development of multiplex tests for GC serum diagnostics. For most of the elements contained in these panels, individual commercial tests are available. Thus, we envision the design of multi-protein assays, incorporating several to all of the panel members, in order to gain a level of specificity that cannot be achieved by testing a single protein alone. As their development and validation will take time, gastritis diagnosis based on the fibrinogen to albumin serum ratio may be a quick way forward. Its determination at the primary/secondary care level for early diagnosis could significantly reduce the number of referrals to endoscopy. Preventive measures are in high demand. The protein marker panels presented in this work will contribute to improved GC diagnostics, once they have been transferred from a research result to a practical tool.
Journal
|
S100A9 (S100 Calcium Binding Protein A9)
|
S100A9 elevation
1d
Inhibitory Effects and Mechanism of the Natural Compound Diaporthein B Extracted from Marine-Derived Fungi on Colon Cancer Cells. (PubMed, Molecules)
The IC50 inhibition effect can be achieved after treatment with 3 μmol/L DTB for 24 h. Compared with the blank group, the migration and clonal-forming ability of colon cancer cells in the DTB group was significantly decreased (p < 0.01), while the apoptotic cells were significantly increased (p < 0.01) in a concentration-dependent manner. DTB can inhibit the proliferation and migration of human colon cancer cells HCT116 and LOVO and promote the apoptosis of human colon cancer cells.
Journal
|
ANXA5 (Annexin A5)
1d
Omega-3 Polyunsaturated Fatty Acids Provoke Apoptosis in Hepatocellular Carcinoma through Knocking Down the STAT3 Activated Signaling Pathway: In Vivo and In Vitro Study. (PubMed, Molecules)
Further, HepG2 cells proliferation was suppressed through inhibition of the STAT3 signaling pathway, cyclin D1, and Bcl-2 activity. Here we report that n-3 PUFAs may be an ideal cancer chemo-preventive candidate by targeting STAT3 signaling, which is involved in cell proliferation and apoptosis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1)
1d
Establishment of prognostic risk model and drug sensitivity based on prognostic related genes of esophageal cancer. (PubMed, Sci Rep)
High expression of HIST1H1E was resistant to trametinib, selumetinib, RDEA119, docetaxel and 17-AAG, High expression of UBE2C was resistant to masitinib, and Low expression of ERO1B made the EC more sensitive to FK866. We constructed an EC risk score model composed of 8 DEGs and gene resistance analysis, which can provide reference for prognosis prediction, diagnosis and treatment of the EC patients.
Journal
|
UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
Mekinist (trametinib) • docetaxel • Koselugo (selumetinib) • refametinib (BAY86-9766) • daporinad (APO866) • Kinaction (masitinib)
1d
m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer. (PubMed, Cell Death Dis)
Together, our findings suggest that LHPP is regulated by m6A methylation and regulates the metabolism of GC by changing the acetylation level. Thus, LHPP is a potential predictive biomarker and therapeutic target for GC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • METTL14 (Methyltransferase 14)
|
HIF1A expression
1d
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers. (PubMed, Med Oncol)
In concordance with patient samples, colorectal cancer cell lines with PIK3CA mutations display more commonly MSI and tend to be more sensitive to PI3K inhibitors. Variability in sensitivity of PIK3CA-mutated cell lines suggests that additional molecular abnormalities contribute to sensitivity.
Preclinical • Journal • Tumor Mutational Burden
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
KRAS mutation • TMB-H • BRAF mutation • PIK3CA mutation
1d
EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. (PubMed, Sci Rep)
Erlotinib, a widely used EGFR inhibitor, downregulated ERK activation in LR cells. Lenvatinib resistance was induced by enhanced EGFR activation, possibly via ROS accumulation, in lenvatinib- resistant cells. These findings may enable the development of lenvatinib combination therapies for HCC.
Journal
|
IR (Insulin receptor)
|
erlotinib • lenvatinib
1d
20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells. (PubMed, Med Oncol)
Furthermore, Rh2 enhanced the therapeutic efficacy of TRAIL in mouse xenograft models, suggesting that Rh2 also sensitizes TRAIL in vivo. Taken together, our study indicates that Rh2 may act as a sensitizer in combination with TRAIL to increase the efficacy of its anti-tumor activity.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • XIAP (X-Linked Inhibitor Of Apoptosis) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
1d
The nutrition-inflammation marker enhances prognostic value to ECOG performance status in overweight or obese patients with cancer. (PubMed, JPEN J Parenter Enteral Nutr)
The LCR is more strongly associated with overall survival than other nutrition-inflammation markers, and it is able to further detect patients with worse prognosis on top of ECOG-PS in overweight or obese patients with cancer.
Journal
|
CRP (C-reactive protein)
1d
Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma - the HEPAR Primary study. (PubMed, J Nucl Med)
Ho-radioembolization is a treatment option with toxicity within the pre-defined limits for a selected group of patients with HCC. Response data support further evaluation.
Journal
|
AFP (Alpha-fetoprotein)
|
Albumin-L
1d
Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis. (PubMed, Cell Death Dis)
And this novel mechanism may have association with poor prognosis. Taken together, targeting CAF-derived CCL5 mediated HIF1α/ZEB1 cascade possibly propose a new therapeutic route for HCC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
1d
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. (PubMed, Nat Commun)
Thus, different TP53 missense mutations contribute differently to cancer progression. Elucidation of the differential impact of distinct TP53 mutations on disease features may make TP53 mutational information more actionable, holding potential for better precision-based medicine.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 R248Q • TP53 R273H
1d
Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis. (PubMed, Nat Commun)
The tissue validation shows that elevated urinary protein biomarkers reflect their alterations in tissue. Here, we show promising urinary protein signatures and provide potential interventional targets to reliably detect CRC, although further multi-center external validation is needed to generalize the findings.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
1d
RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer. (PubMed, Nat Commun)
Crucially, partial genetic downregulation of Srsf1 does not detrimentally affect normal tissue homeostasis, demonstrating that tumour cell plasticity can be differentially targeted. Thus, our findings link dysregulation of the RNA splicing machinery and control of tumour cell plasticity.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
1d
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. (PubMed, Sci Rep)
CAR values were significantly higher as Japan Integrated Staging score increased (p < 0.001). In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.
Journal
|
AFP (Alpha-fetoprotein) • CRP (C-reactive protein)
|
lenvatinib
1d
RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2. (PubMed, Oncogene)
RIOK1-mediated phosphorylation of G3BP2 facilitated ubiquitination of p53 by murine double minute 2 protein (MDM2). Altogether, our study revealed the clinical significance of RIOK1 in CRC, and therapies targeting RIOK1 might alleviate the CRC tumor burden in patients.
Journal
|
MDM2 (E3 ubiquitin protein ligase) • G3BP2 (G3BP Stress Granule Assembly Factor 2)
1d
Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. (PubMed, Mod Pathol)
However, deficient (d) MMR MADs showed fewer CD8 (P = 0.0001), CD163 (P = 0.0001) and PD-L1 (P = 0.003) positive immune cells compared to proficient (p)MMR MADs, a finding also seen with at 10% mucin cut point. Although MAD does not impact DSS, this study raises the possibility that the immune milieu of dMMR MADs and tumors with > =10% mucin may differ from pMMR MADs and tumors with <10% mucin, a finding that may impact immune-oncology based therapeutics.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • MSH6 (MutS homolog 6) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • B2M (Beta-2-microglobulin) • PMS2 (PMS1 protein homolog 2) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
|
BRAF V600E • MSI-H/dMMR • BRAF V600
1d
MiR-6511b-5p suppresses metastasis of pMMR colorectal cancer through methylation of CD44 by directly targeting BRG1. (PubMed, Clin Transl Oncol)
Our data suggest that miR-6511b-5p may act as a promising biomarker and treatment target for pMMR colorectal cancer, particularly in metastatic patients. Mechanistically, miR-6511b-5p suppresses invasion and migration of colorectal cancer cells through methylation of CD44 via directly targeting BRG1.
Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD44
|
MSI-H/dMMR • CD44 expression
1d
Fatty liver progression and carcinogenesis: Beware of pathogenic T cells. (PubMed, Med (N Y))
and Pfister et al. revealed the critical role of CD8 T cells in instigating liver damage and promoting liver cancer in NASH..
Journal
|
CD8 (cluster of differentiation 8)
1d
Exploring the underlying molecular mechanism of liver cancer cells under hypoxia based on RNA sequencing. (PubMed, BMC Genom Data)
Our study may help to understand the potential molecular mechanism of hypoxia in liver cancer.
Journal
|
MIR214 (MicroRNA 214) • MIR483 (MicroRNA 483)
1d
The OmpA of commensal Escherichia coli of CRC patients affects apoptosis of the HCT116 colon cancer cell line. (PubMed, BMC Microbiol)
According to our invitro and insilico investigations, OmpA of gut E.coli strains that belong to the B2 phylogenetic group can affect the eukaryotic cell cycle.
Preclinical • Journal
|
TP53 (Tumor protein P53) • BAX (BCL2-associated X protein)
|
TP53 expression • BAX expression
1d
DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. (PubMed, BMC Cancer)
These findings provide evidence that DAB2IP-based therapy may enhance the anticancer effect of HSP90AA1 inhibitors, and combined targeting of DAB2IP and HSP90AA1 may be a powerful treatment strategy to combat CRC.
Journal
|
HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
1d
A review on the role of DANCR in the carcinogenesis. (PubMed, Cancer Cell Int)
DANCR also regulates activity of PI3K/AKT/NF-κB, Wnt/β-catenin, ERK/SMAD, MAPK, IL-6/JAK1/STAT3, Smad2/3, p53, FAK/PI3K/AKT/GSK3β/Snail pathways. In the current narrative review article, we summarize the roles of DANCR in the carcinogenesis, with an especial emphasis on its role in the development of osteosarcoma and lung, liver, pancreatic and colorectal cancers.
Review • Journal
|
IL6 (Interleukin 6) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR216A (MicroRNA 216a) • MIR335 (MicroRNA 335) • MIR145 (MicroRNA 145) • MIR149 (MicroRNA 149) • SMAD2 (SMAD Family Member 2)
1d
Compound Kushen injection inhibits EMT of gastric cancer cells via the PI3K/AKT pathway. (PubMed, World J Surg Oncol)
AKT1 is a key gene for CKI treatment of GC. CKI inhibited GC cell growth and migration and induced GC cell apoptosis. In addition, CKI regulated the EMT process in GC cells through the PI3K/AKT signalling pathway.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1)
1d
A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. (PubMed, J Nanobiotechnology)
We discovered a VHH-Fc fusion protein with high affinity to ANGPTL3, strong stability and also alleviated the progression of NAFLD, which might offer a promising therapy for NAFLD.
Journal
|
LPL (Lipoprotein Lipase)
|
Evkeeza (evinacumab)
1d
5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone up-regulates miR-145 expression and inhibits proliferation of gastric cancer cells. (PubMed, Arch Med Sci)
In addition, THDMF promoted miR-145 expression and down-regulation of PI3K/AKT signalling pathway in MKN28 cells. Therefore, THDMF may be utilised as a potential novel therapeutic agent for the treatment of gastric cancer.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MIR145 (MicroRNA 145)
|
MYC expression
1d
A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma. (PubMed, Front Genet)
Our study demonstrated that a panel of E2F target genes signature including five genes could predict the prognosis of hepatocellular carcinoma. This panel gene signature can facilitate the development of individualized and effective treatment for hepatocellular carcinoma.
Journal • Gene Signature
|
CDCA3 (Cell Division Cycle Associated 3) • CDCA8 (Cell Division Cycle Associated 8) • JPT1 (Jupiter Microtubule Associated Homolog 1) • SSRP1 (Structure Specific Recognition Protein 1)
1d
Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation. (PubMed, Evid Based Complement Alternat Med)
In addition, FDY003 was shown to target diverse key pathways associated with PC pathophysiology, namely, the PIK3-Akt, MAPK, FoxO, focal adhesion, TNF, p53, HIF-1, and Ras pathways. Our network pharmacological findings advance the mechanistic understanding of the anti-PC properties of FDY003 from a system perspective.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
1d
LINC01232 Promotes Metastasis and EMT by Regulating miR-506-5p/PAK1 Axis in Gastric Cancer. (PubMed, Cancer Manag Res)
PAK1 was certified to be a target of miR-506-5p, inhibition of PAK1 could interrupt LINC01232 overexpression-induced migration of gastric cancer cells. The LINC01232/miR-506-5p/PAK1 axis promotes metastasis of gastric cancer cells.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • MIR506 (MicroRNA 506)
1d
Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma. (PubMed, Cureus)
In contrast to all cohorts, in Asian and black patients, there was no difference in actionable genomic landscape between the primary and metastatic tumor tissues. Conclusion This study had the largest number of colon cancer patients that evaluated the actionable genomic alterations in primary and metastatic tumor tissues. BRAF and MMR gene alterations were more frequent in the primary tumor tissues than the metastatic tumor tissues.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • HER-2 amplification • BRAF mutation • NTRK1 fusion • NTRK3 fusion
1d
Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology. (PubMed, J Hepatocell Carcinoma)
SHC1, SLAMF8 and IL-32 can differentiate among patients with HCC, LF/LC, CHB and healthy controls. More importantly, the APFSSI model greatly improves the diagnostic accuracy of HBV-associated liver diseases.
Journal
|
IL32 (Interleukin 32) • SLAMF8 (SLAM Family Member 8)
1d
CircFGGY Inhibits Cell Growth, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma via Regulating the miR-545-3p/Smad7 Axis. (PubMed, Front Cell Dev Biol)
In addition, miR-545-3p, a tumor promoter targeting both circFGGY and Smad7, suppressed the upregulation of Smad7 caused by circFGGY overexpression. Collectively, our data revealed that circFGGY inhibits the proliferation and invasion of HCC cells by sponging miR-545-3p and promote the expression of Smad7, indicating that circFGGY functions as a tumor suppressor and could be a prognostic biomarker for HCC.
Journal
|
SMAD7 (SMAD Family Member 7)
1d
Cedrus atlantica extract exerts antiproliferative effect on colorectal cancer through the induction of cell cycle arrest and apoptosis. (PubMed, Food Sci Nutr)
CAt showed significant inhibitory effects on the proliferation of HT-29 and CT-26 cells, and combined with the clinical drug, 5-fluorouracil (5-FU), exhibited synergistic effects...Importantly, CAt suppressed tumor progression and prolonged the life span of mice within a well-tolerated dose. Therefore, our findings provide novel insights into the use of CAt for the treatment of CRC.
Journal
|
CASP8 (Caspase 8) • CASP9 (Caspase 9) • FASLG (Fas ligand) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
5-fluorouracil
1d
2-Pyridin-4-yl-methylene-beta-boswellic Acid-A Potential Candidate for Targeting O-Methylguanine-DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D-Microsatellite Stable, G12V-Microsatellite Instable Mutant Colon Cancer. (PubMed, ACS Pharmacol Transl Sci)
Comprehensively, PMBA represents a new class of KRAS inhibitors having a therapeutic window in the scope of a drug candidate. The findings suggest that the PMBA analogue could inhibit the growth of human CRC in vivo through downregulation of cancer-associated biomarkers as well as reactivate expression of the MGMT gene associated with increased H3K9 acetylation and H3K4 methylation with facilitated transcriptional activation, which might be important in silencing of genes associated with upregulation in the activity of KRAS.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
KRAS mutation • KRAS G12V • KRAS G13D • MGMT promoter methylation • KRAS G13 • KRAS G12
1d
Identification of m6A-Related lncRNA to Predict the Prognosis of Patients with Hepatocellular Carcinoma. (PubMed, Biomed Res Int)
Moreover, high expression of SNHG1 or SNHG3 resulted in drug resistant to AKT inhibitor VII, bexarotene, bicalutamide, dasatinib, erlotinib, and gefitinib. We established a nomogram to systematically predict the 5- and 8-year overall survival of liver cancer patients with good accuracy. Finally, the in vitro assays suggest that SNHG1 and SNHG3 promote the proliferative, migratory, and invasive abilities of HCC cells.
Journal
|
SNHG1 (Small Nucleolar RNA Host Gene 1)
|
dasatinib • erlotinib • gefitinib • bicalutamide • Targretin oral (bexarotene oral)
1d
Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer. (PubMed, Front Cell Infect Microbiol)
Taking together, our study proved that HBV infection is an independent prognostic factor in GC patients. The unique mutation profiles of HBV-infected patients with GC open a new research direction toward the underling mechanism between HBV infection and GC.
Journal
|
KMT2D (Lysine Methyltransferase 2D)
1d
Development of a Bile Acid-Related Gene Signature for Predicting Survival in Patients with Hepatocellular Carcinoma. (PubMed, Comput Math Methods Med)
The three-gene prediction model was more reliable than the pathological staging characters of the tumor for the prognosis and survival of patients with HCC. In addition, the upregulated genes facilitating the transport of BAs are associated with poor prognosis of patients with HCC, and genes of de novo synthesis of BAs benefit patients with HCC.
Journal • Gene Signature
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • SLC51B (Solute Carrier Family 51 Subunit Beta)
1d
PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. (PubMed, Dis Markers)
CDK1, PITX2, PRKAA2, and SFN were all upregulated in the tumor tissue of clinical samples. A putative and differential dataset-validated prognostic signature on the basis of integrated bioinformatic analysis was established in our study, providing the immunotherapeutic targets as well as the personalized treatment in HCC with neoteric insight.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • BTLA (B And T Lymphocyte Associated) • CDK1 (Cyclin-dependent kinase 1)
1d
Carbon Material Hybrid Construction on an Aptasensor for Monitoring Surgical Tumors. (PubMed, J Anal Methods Chem)
The limit of detection for CEA in PBS and serum is calculated from a linear regression graph to be 0.5 ng/mL with R values of 0.9593 and 0.9657, respectively, over a linear range from 0.5 to 500 ng/mL. This CEA quantification by the aptasensor can help diagnose various surgical tumors and monitor their progression.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression • CEACAM5 overexpression
1d
Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. (PubMed, Toxicol Mech Methods)
Consequently, Withaferin A may attenuate the metastatic potential and sorafenib resistance by regulating Keap1/Nrf2-associated EMT and ferroptosis. Thus, Withaferin A may serve as a promising agent for HCC therapy, especially for advanced HCC.
Journal
|
CDH5 (Cadherin 5)
|
KEAP1 expression
|
Nexavar (sorafenib)
1d
NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. (PubMed, Mol Oncol)
Finally, we proved that NNK intervention could not only activate β2AR, but also increase its expression, making β2AR and Akt form a feedback loop. Overall, these findings show that the NNK-induced β2AR-Akt feedback loop promotes stemness and gemcitabine resistance in pancreatic cancer cells.
Journal
|
ATG7 (Autophagy Related 7) • BECN1 (Beclin 1)
|
gemcitabine
1d
Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. (PubMed, Cancer Med)
The IFIT3, PARP9, TAP1, STAT1, and OAS2 were confirmed as hub genes, and COAD patients with higher expressions of these genes might be more appropriate for mRNA vaccination. In conclusion, the IGF2BP3, DPCR1, HOXD10, TRIM7, and ZIC5 were identified as potential candidates for developing mRNA vaccines against COAD, and patients in IS1 and IS5 subtypes might respond better to mRNA vaccination.
Journal • Tumor Mutational Burden • PARP Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TAP1 (Transporter 1)
1d
SPP1 promotes radiation resistance through JAK2/STAT3 pathway in esophageal carcinoma. (PubMed, Cancer Med)
Collectively, these findings suggested that the SPP1/JAK2/STAT3 axis is a critical player in ESCA progression and radiation resistance, which is a potential therapeutic target for combined therapy with the standard radiotherapy regimen to improve curative effect and increase patients' survival with ESCA.
Journal
|
SPP1 (Secreted Phosphoprotein 1)
1d
NEDD4L inhibits cell viability, cell cycle progression, and glutamine metabolism in esophageal squamous cell carcinoma via ubiquitination of c-Myc. (PubMed, Acta Biochim Biophys Sin (Shanghai))
NEDD4L inhibits cell viability, cell cycle progression, and glutamine metabolism in ESCC by ubiquitination of to decrease the expressions of GLS1 and SLC1A5. Our findings highlight the importance of NEDD4L/c-Myc signaling in ESCC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SLC1A5 (Solute Carrier Family 1 Member 5) • GLS1 (Glutaminase)
1d
Investigation of Vascular Endothelial Growth Factor Polymorphisms on Risk, Metastasis, Laterality, and Prognosis of Colorectal Cancer in Turkish Subjects. (PubMed, Genet Test Mol Biomarkers)
Patients with VEGF +405GG genotype showed longer progression-free survival as a response to bevacizumab treatment (Log rank = 6.92, p = 0.03). According to our results, VEGF +405G>C and -460C>T polymorphisms were found to be associated with CRC prognosis, sidedness, and metastasis. Our findings should be conducted in further studies.
Journal
|
VEGFA (Vascular endothelial growth factor A)
|
Avastin (bevacizumab)
1d
P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis. (PubMed, PLoS One)
In conclusion, these findings constitute the evidence that P2X4 receptors in the presence of HCV play a significant role in the regulation of key antioxidant enzymes (HO-1, Cu/ZnSOD), in the induction of proinflammatory. cytokine (TNF-α), profibrotic cytokine (TGF-β) vasoactive cytokine (angiotensin II). P2X4 also increases the expression of extracellular matrix proteins (laminin and elastin) in the presence of HCV.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • LEP (Leptin)
1d
Cytopathology of solid pancreatic neoplasms: An algorithmic approach to diagnosis. (PubMed, Cancer Cytopathol)
The objective of this review is to expand the understanding of the cytomorphology of solid pancreatic neoplasms using an integrated, multidisciplinary approach in their diagnosis. Knowledge and understanding of recent updates in the classification of solid pancreatic neoplasms ensures that cytopathologists appropriately triage specimens, judiciously use and interpret ancillary studies, and incorporate these results in reporting.
Review • Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SYP (Synaptophysin)
1d
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. (PubMed, Eur J Cancer)
A relevant attrition rate across subsequent lines of therapy is evident, and more pronounced in RAS and BRAF mutated patients, thus highlighting the relevance of the choice of the upfront treatment. The efficacy of anti-EGFR agents among RAS/BRAF wild-type patients unexposed to anti-EGFRs is higher than other options. The reintroduction of chemotherapy remains frequent in clinical practice.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
5-fluorouracil • oxaliplatin • leucovorin calcium
1d
Design, synthesis and antitumour activity of novel 5(6)-amino-benzimidazolequinones containing a fused morpholine. (PubMed, Eur J Med Chem)
In vivo studies showed that compound a21-2 inhibits the growth of tumours in nude mice without significant systemic toxicity. These findings suggest that compound a21-2 represents a promising candidate antitumour drug.
Journal
|
CHEK2 (Checkpoint kinase 2) • MAPK8 (Mitogen-activated protein kinase 8)
1d
Tirapazamine-loaded CalliSpheres microspheres enhance synergy between tirapazamine and embolization against liver cancer in an animal model. (PubMed, Biomed Pharmacother)
We revealed the improved synergistic anti-tumor effects of CSMTPZ therapy in the rabbit VX2 liver cancer model. Our data support the clinical evaluation of CSMTPZs in the treatment of hepatocellular carcinoma, and CSMTPZ administration might serve as a successful therapeutic strategy for this malignancy.
Preclinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
Tirazone (tirapazamine)
1d
Bioassay-guided isolation of anti-tumor polyprenylphloroglucinols from Calophyllum polyanthum and primary mechanism. (PubMed, Biomed Pharmacother)
It could significantly up-regulate the expression levels of apoptosis-related genes (BAX, Caspase-9,) and proteins (BAX, Cleaved-caspase-9, Cleaved-caspase-3) and down-regulated the expression of inhibitor of apoptosis gene (Bcl-2) and proteins (Bcl-2, phosphorylated AKT). Possible mechanism of the antitumor activity of apetalic acid derived from Calophyllum polyanthum supports its use in the prevention and treatment of colorectal cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
1d
Sparstolonin B inhibits pancreatic adenocarcinoma through the NF-κB signaling pathway. (PubMed, Exp Cell Res)
The treatment group (26 μmol/L) had reduced graft volume and weight and fewer Ki-67-positive cells than the control group. Therefore, Sparstolonin B can inhibit the growth and induce the apoptosis of pancreatic cancer cells via the NF-κB signaling pathway and may be a potential novel drug for pancreatic cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • NFKBIA (NFKB Inhibitor Alpha 2) • RELA (RELA Proto-Oncogene)
1d
Discovery proteomics analysis determines that driver oncogenes suppress antiviral defense pathways through reduction in interferon-b autocrine stimulation. (PubMed, Mol Cell Proteomics)
In particular, there was dramatically lower expression of dsRNA sensors including DDX58 (RIG-I) and OAS proteins, which resulted in attenuated functional responses when the oncogenic cells were treated with the dsRNA mimetic, polyI:C, and increased susceptibility to infection with an RNA virus. Our reductionist approach provides molecular and functional insights connected to immune evasion hallmarks in cancers and suggests therapeutic opportunities.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • DDX58 (DExD/H-Box Helicase 58)
1d
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). (PubMed, Int J Surg)
Tislelizumab plus chemotherapy as neoadjuvant therapy demonstrates promising antitumor activity for resectable ESCC with high rates of MPR, pCR, and R0 resection, as well as acceptable tolerability.
P2 data • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression
|
carboplatin • albumin-bound paclitaxel • Baize’an (tislelizumab)
1d
Marsdenia tenacissima (Roxb.) Moon injection exerts a potential anti-tumor effect in prostate cancer through inhibiting ErbB2-GSK3β-HIF1α signaling axis. (PubMed, J Ethnopharmacol)
This study proposed that MTE exerts a potential anti-tumor effect in PCa through inhibiting ErbB2-GSK3β-HIF1α signaling axis, which may be related to the TCA cycle.
Journal
|
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
1d
Role of Epstein Barr Virus Gene on the Interleukin-1 Receptor-1 Expression in B Lymphoma and Gastric Cancer Cell Lines (ASM Microbe 2022)
Epstein Barr virus employs LMP1 and EBNA1 to attenuate IL1R1 signaling to avoid host immune surveillance, attack and clearance. Silencing these two proteins can serve as potential therapeutic target to improve host immune system fight against EBV infected B lymphoma and gastric cancer cell.
Preclinical
|
IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I)
2d
Angiopoietin-like 4 promotes glucose metabolism by regulating glucose transporter expression in colorectal cancer. (PubMed, J Cancer Res Clin Oncol)
ANGPTL4 regulates the expression of GLUTs by activating the PI3K-AKT pathway and thereby promoting glucose metabolism in CRC. These findings establish a new functional role of ANGPTL4 in cancer progression and lay the foundation for developing a novel therapeutic target.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
2d
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming. (PubMed, Cell Mol Gastroenterol Hepatol)
Our study provides fundamental knowledge on the mechanisms underlying the formation of the fibroinflammatory stroma in pancreatic cancer and highlights stromal pathways with the potential to be exploited therapeutically.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
2d
Silencing of RND3/RHOE inhibits the growth of human hepatocellular carcinoma and is associated with reversible senescence. (PubMed, Cancer Gene Ther)
Interestingly, after re-expression of RND3, these cells are able to bypass senescence and regain the ability to proliferate, with a re-expression of hTERT. Given that a low expression of Rnd3 is linked to the presence of satellite nodules in HCC, the transient senescence state observed might play a role in cancer progression.
Journal
|
TERT (Telomerase Reverse Transcriptase)
2d
Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia. (PubMed, Cell Mol Gastroenterol Hepatol)
In addition to showing cooperation between the Myc and Mlx Networks, this study showed the latter to be more important in maintaining proliferative, metabolic, and translational homeostasis, while concurrently serving as a suppressor of benign tumorigenesis. GEO accession numbers: GSE181371, GSE130178, and GSE114634.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
2d
Evaluation of the human hazard of the liver and lung tumors in mice treated with permethrin based on mode of action. (PubMed, Crit Rev Toxicol)
The evidence strongly indicates that Club cell mitogens are not likely to lead to increased susceptibility to lung tumor development in humans. Overall, based on MOA evaluation it is concluded that permethrin does not pose a tumorigenic hazard for humans, this conclusion being supported by negative data from permethrin epidemiological studies.
Preclinical • Review • Journal
|
PPARA (Peroxisome Proliferator Activated Receptor Alpha)
2d
Regulation of human UDP-glycosyltransferase (UGT) genes by miRNAs. (PubMed, Drug Metab Rev)
Collectively, these observations demonstrate that miRNAs represent important post-transcriptional regulators of the UGT gene superfamily. In this article, we present a comprehensive review of reported UGT/miRNA regulation studies, describe polymorphisms within functional miRNA target sites that may affect their functionalities, and discuss potential cooperative and competitive regulation of UGT mRNAs by miRNAs through adjacently located miRNA target sites.
Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
2d
Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype 3 axis. (PubMed, Anticancer Drugs)
Moreover, circSAMD4A knockdown improved 5-Fu sensitivity of CRC in vivo. CircSAMD4A contributed to 5-Fu resistance of CRC cells partly through upregulating PFKFB3 expression by sponging miR-545-3p, providing a possible circRNA-targeted therapy for CRC.
Journal
|
PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
|
5-fluorouracil
2d
Effects of probiotics on gastric cancer-related inflammation: A systematic review and meta-analysis. (PubMed, J Food Biochem)
Probiotics can reduce gastric cancer-related inflammation levels more effectively by increasing the levels of cluster of differentiation 4 and greatly reducing the levels of interleukin-6. The study provides some theoretical basis for controlling cancer-related inflammation responses in the patients using probiotics.
Retrospective data • Review • Journal
|
IL6 (Interleukin 6)
2d
Journal
|
mTOR (Mechanistic target of rapamycin kinase)
2d
Rational design, synthesis and activities of phenanthrene derivatives against hepatic fibrosis. (PubMed, Fitoterapia)
Further studies implied that they inhibited the LPS-initiated cellular liver fibrosis through inhibition the secretion of TNF-α, IL-1β, TGF-β1 and α-SMA. From these data, a picture emerges wherein a novel idea using phenanthrenes A-1 and B-1 as potential candidates to treat liver fibrosis for further animal studies.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta)
2d
LncRNA SNHG11 enhances bevacizumab resistance in colorectal cancer by mediating miR-1207-5p/ABCC1 axis. (PubMed, Anticancer Drugs)
In addition, exosomal SNHG11 was upregulated in bevacizumab-resistant CRC cells. SNHG11 contributes to bevacizumab resistance in CRC depending on the modulation of miR-1207-5p and ABCC1.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • SNHG1 (Small Nucleolar RNA Host Gene 1) • MIR1207 (MicroRNA 1207) • SNHG11 (Small Nucleolar RNA Host Gene 11)
|
Avastin (bevacizumab)
2d
Defining Novel DNA Virus-Tumor Associations and Genomic Correlates using Prospective Clinical Tumor/Normal Matched Sequencing Data. (PubMed, J Mol Diagn)
HR HPV and EBV associated tumors show newly discovered genomic associations including a lower tumor mutation burden (TMB). The study demonstrates the ability to study the role of DNA viruses in human cancer from clinical genomics data and establishes the largest cohort which can be utilized as a validation set for future discovery efforts.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
|
TMB-L
2d
Colon cancer diagnosis and staging classification based on machine learning and bioinformatics analysis. (PubMed, Comput Biol Med)
Finally, the RF model had the best results in the diagnosis of colon cancer versus control group fold cross-validation with an average accuracy of 99.81%, F1 value reaching 0.9968, accuracy of 99.88%, and recall of 99.5%, and an average accuracy of 91.5%, F1 value reaching 0.7679, accuracy of 86.94%, and recall in the diagnosis of colon cancer stages I, II, III and IV. The recall rate reached 73.04%, and eight genes associated with colon cancer prognosis were identified for GCNT2, GLDN, SULT1B1, UGT2B15, PTGDR2, GPR15, BMP5 and CPT2.
Journal
|
UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
2d
Association of CD103+ T cell infiltration with overall survival in solid tumors of the digestive duct and its potential in anti-PD-1 treatment: A review and meta-analysis. (PubMed, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub)
The pooled result indicated that CD103+ T cell infiltration in solid tumors of the digestive duct may possess predictive value for prognosis. Preclinical studies suggested that CD103+ T cell infiltration could predict response to anti-PD-1/PD-L1 treatment.
Retrospective data • Review • Journal
|
CD4 (CD4 Molecule) • ITGAE (Integrin Subunit Alpha E)
2d
The CD133CXCR4 Colorectal Tumor Cells Promote Colorectal Cancer Progression by PI3K/AKT Signaling. (PubMed, J Interferon Cytokine Res)
We also showed that CD133CXCR4 induced significant phosphorylation of PI3K/AKT. In conclusion, our data demonstrate that CD133CXCR4 cell subsets play an important role in the development and progression of colon cancer.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD133
|
CD133 expression
2d
Antitumor mechanisms of an exopolysaccharide from Lactobacillus fermentum on HT-29 cells and HT-29 tumor-bearing mice. (PubMed, Int J Biol Macromol)
Moreover, YL-11 EPS can block the PI3K/AKT signaling pathway and arrest the cell cycle in G1-phase to exert its anti-colon cancer activity. Overall, YL-11 EPS can be explored as a potential nutraceutical to prevent colorectal cancer.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
2d
RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an mA-YTHDF2-dependent manner. (PubMed, Oncogene)
PDGFC upregulation led to reactivation of the Akt signaling pathway, promoting cell growth. Overall, our study reveals that FTO downregulation leads to increased mA modifications in the 3' UTR of PDGFC and then modulates the degradation of its transcriptional level in an mA-YTHDF2-dependent manner, highlighting a potential therapeutic target for PDAC treatment and prognostic prediction.
Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • PDGFC (Platelet Derived Growth Factor C) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
FTO expression
2d
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. (PubMed, Epigenomics)
Higher ratios at best response were associated with shorter progression-free survival. The authors suggest that circulating H3K27me3/H3K36me3 ratio level acts as a predictive biomarker for sorafenib treatment outcomes in patients with advanced hepatocellular carcinoma.
Journal
|
SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
Nexavar (sorafenib)
2d
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells. (PubMed, Cancer Lett)
IMPLICATIONS: This study supports the notion that DNA replication-initiation proteins (DRIPs), including MCM2-7 proteins, are attractive anticancer targets. Furthermore, the potential of miR-214 as an anticancer agent, with activity against liver cancer cells but not normal livre cells, may be of high significance.
Journal
|
MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR214 (MicroRNA 214)
2d
Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy. (PubMed, ACS Appl Mater Interfaces)
The thus released siRNA could downregulate the expressions of Kras, GLS1, and other enzymes involved in glucose metabolism, resulting in the downregulations of ATP and other metabolites. Such a biosafe LDH/siRNA nanomedicine is able to efficiently suppress the growth of xenografts through cancer cell proliferation suppression, displaying its great potential as a simultaneous glucose/glutamine metabolism coinhibitor for treating pancreatic cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • GLS1 (Glutaminase)
|
KRAS mutation • KRAS expression
2d
Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. (PubMed, Cancer Lett)
This is the first preclinical study using a humanized mouse model for new combination immunotherapeutic development and supports the further clinical testing of aIL-8 in combination with aPD-1 for PDAC treatment. This study also suggests that peripherally derived myeloid cells can potentiate the antitumor response of T cells, likely through the innate immune response, and aIL-8 re-educates tumor-infiltrating myeloid cells by activating the innate immune response.
Preclinical • Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD14
2d
Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. (PubMed, Front Immunol)
We also identified SPP1 TAMs as an independent adverse prognostic indicator for survival in ICC. Our analyses provide an overview of the altered tumor ecosystem in ICC treated with ICBs and highlight the potential role of targeting CAFs and SPP1TAMs in developing a more rational checkpoint blockade-based therapy for ICC.
Journal • Checkpoint inhibition
|
FLT1 (Fms-related tyrosine kinase 1) • SPP1 (Secreted Phosphoprotein 1)
2d
Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. (PubMed, Oncoimmunology)
Furthermore, Toll-like receptor 4 (TLR4) agonist could diminish the macrophage (M2) polarization and reverse the M2-mediated DTA-1 resistance, eliciting robust antitumor effect in HCC. Our finding demonstrated that the TLR4 agonist synergized with DTA-1 was a potential strategy for HCC treatment.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • IL4 (Interleukin 4)
2d
Cancer genetic testing in marginalized groups during an era of evolving healthcare reform. (PubMed, J Cancer Policy)
Cancer genetic testing and screening to date have only partially benefited from healthcare reforms. Sensitivity to cost concerns and further monitoring of emerging data are needed. A reduction in disparities depends on the availability of private insurance, Medicaid and Medicare to the marginalized. Attention to value-based design and the way cancer benefits are translated into actual testing and screening are crucial.
Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
2d
Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma. (PubMed, Clin Exp Immunol)
Furthermore, IGF1Rhi Tregs exhibited higher phosphorylation of the mammalian target of the rapamycin complex 1 (mTORC1) in vivo...Furthermore, malignant cells in the tumor nodules induced IGF1R down-regulation in Tregs at the mRNA level. In summary, we identified the heterogeneity of intrahepatic Tregs in HCC which might play significant roles in tumor immunity.
Preclinical • Journal • IO biomarker
|
IGF1R (Insulin-like growth factor 1 receptor) • TGFB1 (Transforming Growth Factor Beta 1) • IL10 (Interleukin 10)
|
IGF1R expression
|
sirolimus
2d
Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England. (PubMed, Clin Oncol (R Coll Radiol))
Our results support the publication of national outcome data. If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment.
Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
Erbitux (cetuximab) • Nexavar (sorafenib) • gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • Lonsurf (trifluridine/tipiracil)
2d
A novel 3'tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer. (PubMed, Cell Death Dis)
Mechanistically, tRF-Val directly bound to the chaperone molecule EEF1A1, mediated its transport into the nucleus and promoted its interaction with MDM2 (a specific p53 E3 ubiquitin ligase), thus inhibiting the downstream molecular pathway of p53 and promoting GC progression. These findings provided a new potential therapeutic target for GC and a new explanation for the occurrence of GC.
Journal
|
MDM2 (E3 ubiquitin protein ligase) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
2d
Enhanced anticancer potency with reduced nephrotoxicity of newly synthesized platin-based complexes compared with cisplatin. (PubMed, Sci Rep)
Real time PCR and western analysis demonstrated that the expression pattern of apoptotic genes and proteins is according to the intrinsic apoptosis pathway through the Bax/Bcl-2-Casp9-Casp3/Casp7 axis. Collectively, our findings indicated that the Pt(TSC)Cl complex triggers apoptosis in Caco-2 cell lines, while low nephrotoxicity was shown and may be considered a useful anticancer drug candidate for colorectal cancers for further optimization and growth.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • CASP7 (Caspase 7)
|
cisplatin
2d
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability. (PubMed, Sci Rep)
Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib...Homoharringtonine (HHT) is a first-in-class inhibitor of protein biosynthesis and is FDA-approved for the treatment of chronic myeloid leukemia (CML) that is resistant to at least two TKIs...The antitumor activity of HHT was confirmed in a GIST xenograft model. Taken together, inhibition of protein biosynthesis is a promising strategy to overcome TKI resistance in GIST.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT mutation • KIT expression
|
imatinib • Sutent (sunitinib) • Stivarga (regorafenib) • Qinlock (ripretinib) • Synribo (omacetaxine mepesuccinate)
2d
Nanocurcumin and curcumin prevent N, N'-methylenebisacrylamide-induced liver damage and promotion of hepatic cancer cell growth. (PubMed, Sci Rep)
Nanocurcumin also reduced the histopathology and fibrosis caused by AC, and reversed AC-induced glycogen depletion. Nanoparticle formulation can increase the anticancer and hepatoprotective efficiencies of curcumin.
Journal
|
TP53 (Tumor protein P53) • CASP3 (Caspase 3) • COL1A1 (Collagen, type I, alpha 1)
|
TP53 expression
2d
A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. (PubMed, Clin J Gastroenterol)
No viable tumor cells remained on histological analyses. The patient is doing well without any signs of recurrence at 3 months after conversion surgery.
Journal • PD(L)-1 Biomarker
|
AFP (Alpha-fetoprotein)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
2d
Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study. (PubMed, Int J Colorectal Dis)
This study indicated the prevalence of FGFR2 and HER2 in GC and CRC in the Japanese population. The screening performed in this study could be useful for identifying eligible patients for future clinical trials of agents targeting these proteins.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 positive • HER-2 expression • FGFR2 expression
2d
ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment. (PubMed, Oxid Med Cell Longev)
Finally, the two miRNAs suppressed cell proliferation, migration, and invasion and promoted apoptosis in huh7 and smmc7721 cells. It indicated that ROS might affect the prognosis of HCC patients through immune response and increase the sensitivity of HCC patients to radiotherapy and chemotherapy.
Journal
|
MIR106A (MicroRNA 106a) • MIR210 (MicroRNA 210)
2d
Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis. (PubMed, Int J Gen Med)
The role of these E2F family members in disease pathology may be related to their functions in cell cycle regulation, therapeutic resistance, immune cell infiltration, and epithelia-to-mesenchymal transition. Further studies are required to validate our results; however, our findings may help provide a foundation for broadening our understanding of CRC pathology.
Journal
|
E2F1 (E2F transcription factor 1) • E2F2 (E2F Transcription Factor 2) • E2F3 (E2F transcription factor 3)
2d
LINC00586 Represses ASXL1 Expression Thus Inducing Epithelial-To-Mesenchymal Transition of Colorectal Cancer Cells Through LSD1-Mediated H3K4me2 Demethylation. (PubMed, Front Pharmacol)
An ASXL1 gene resisting to LINC00586 attack was demonstrated in cultured HCT116 and LoVo cells and mouse xenograft models of human CRC. Overall, discovery of the LINC00586/LSD1/ASXL1 axis partially explains epigenetic mechanism regulating EMT in CRC, providing a therapeutic target to limit CRC metastasis.
Journal
|
ASXL1 (ASXL Transcriptional Regulator 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CDH1 expression • VIM expression
2d
c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer. (PubMed, Front Pharmacol)
In summary, our data revealed that the mechanism of dFdC resistance may be that c-Myc overexpression contributed to increased PD-L1 expression, and ARTS could overcome dFdC-resistant pancreatic cancer by inhibiting c-Myc and PD-L1. Our findings not only suggest c-Myc and PD-L1 as novel prognostic biomarkers in dFdC-resistant pancreatic cancer, but also provide ARTS as a promising candidate for overcoming dFdC resistance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
PD-L1 expression • MYC overexpression • MYC expression
|
gemcitabine
2d
DNAJA1 Stabilizes EF1A1 to Promote Cell Proliferation and Metastasis of Liver Cancer Mediated by miR-205-5p. (PubMed, J Oncol)
The mRNA levels of miR-205-5p and DNAJA1 were negatively correlated in liver cancer. In conclusion, our study reveals that DNAJA1 acts as an oncogene in liver cancer via miR-205-5p/EF1A1 axis and might be a potential biomarker to predict the prognosis for liver cancer patients.
Journal
|
AFP (Alpha-fetoprotein) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • MIR205 (MicroRNA 205)
2d
ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC. (PubMed, Front Oncol)
Mouse subcutaneous tumors with ACYP1 overexpression exhibited significantly accelerated tumor progression with increased aggregation of CD4+ T cells. Overall, ACYP1 may serve as a vital prognostic biomarker and play an immunoregulatory role in LIHC.
Journal • Pan tumor
|
CD4 (CD4 Molecule)
2d
Lipolysis-Stimulated Lipoprotein Receptor Impairs Hepatocellular Carcinoma and Inhibits the Oncogenic Activity of YAP1 via PPPY Motif. (PubMed, Front Oncol)
Thus, LSR increases the phosphorylation of YAP1 and impairs the growth of HCC. This highlights that targeting LSR might be a promising therapeutic strategy for HCC.
Journal
|
YAP1 (Yes associated protein 1) • LSR (Lipolysis Stimulated Lipoprotein Receptor)
2d
Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of PLOD2. (PubMed, Front Genet)
Lastly, twenty pairs of gastric cancer and adjacent immunohistochemistry showed that PLOD2 was significantly overexpressed in gastric cancer (p < 0.001). Collectively, PLOD2 played a significant role in tumorigenesis and maybe serve as a potential biomarker for diagnosis and prognosis in cancers.
Journal • Tumor Mutational Burden • IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
|
PLOD2 overexpression
2d
Molecular Subtyping of Cancer Based on Distinguishing Co-Expression Modules and Machine Learning. (PubMed, Front Genet)
When applied to breast cancer (BRCA) and stomach adenocarcinoma (STAD) molecular subtyping, it has superior classification performance over existing methods. In addition to improving classification performance, we consider the specific co-expressed modules selected for subtyping to be biologically meaningful, which potentially offers new insight for diagnostic biomarker design, mechanistic studies of cancer, and individualized treatment plan selection.
Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset)
2d
Inhibitory Effect of Lotus Leaf-Enriched Flavonoid Extract on the Growth of HT-29 Colon Cancer Cells through the Expression of PI3K-Related Molecules. (PubMed, Biomed Res Int)
The high-performance liquid chromatography (HPLC) results showed that kaempferin, hyperoside, astragaloside, phloridzin, and quercetin were the main chemical constituents of lotus leaf. Lotus leaves contain functional flavonoids that inhibit the proliferation of HT-29 colon cancer cells and regulate the expression of PI3K/Akt through five important chemicals.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CAT (Catalase) • PI3K (Phosphoinositide 3-kinases)
2d
In-depth proteomics characterization of ∆Np73 effectors identifies key proteins with diagnostic potential implicated in lymphangiogenesis, vasculogenesis and metastasis in colorectal cancer. (PubMed, Mol Oncol)
We found an important association between the overexpression of ∆Np73 and effectors related to lymphangiogenesis, vasculogenesis and metastasis, such as brain-derived neurotrophic factor (BDNF) and the putative aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (EMAP-II)-vascular endothelial growth factor C (VEGFC)-vascular endothelial growth factor receptor 3 (VEGFR3) axis. We further demonstrated the usefulness of BDNF as a potential CRC biomarker able to discriminate between CRC patients and premalignant individuals from controls with high sensitivity and specificity.
Journal
|
FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C) • BDNF (Brain Derived Neurotrophic Factor)
2d
Differential expression of metallothionein and p21 in gastric cancer and some precursor lesions. (PubMed, Eur Rev Med Pharmacol Sci)
Both MT and p21 may have a role in the development and progression of GC, and both proteins may be useful for selecting targeted therapy for GC patients.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
2d
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer. (PubMed, Eur Rev Med Pharmacol Sci)
As well as, lower expression of MLH1, MSH2, MSH6, PMS2, EPCAM and MUTYH genes were recognized in LS patients and future CRC Saudi patients. These gene mutations may be used as diagnostic and/or prognostic genetic markers in CRC Saudi patients and could offer a potential therapeutic target for CRC management.
Review • Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • NOTCH1 (Notch 1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CRLF2 (Cytokine Receptor Like Factor 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MSH6 (MutS homolog 6) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PMS2 (PMS1 protein homolog 2) • TNFA (Tumor Necrosis Factor-Alpha) • CHEK2 (Checkpoint kinase 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • CHEK1 (Checkpoint kinase 1) • MMP2 (Matrix metallopeptidase 2) • NOTCH3 (Notch Receptor 3) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • EPCAM (Epithelial cell adhesion molecule) • MIR34A (MicroRNA 34a-5p) • MUTYH (MutY homolog) • IL17A (Interleukin 17A) • TLR4 (Toll Like Receptor 4) • MIR182 (MicroRNA 182) • NOTCH4 (Notch 4) • TSLP (Thymic Stromal Lymphopoietin) • XRCC1 (X-Ray Repair Cross Complementing 1) • FOXM1 (Forkhead Box M1) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • MIR29A (MicroRNA 29a) • TLR9 (Toll Like Receptor 9)
|
NOTCH3 mutation • PIK3CA expression • EPCAM expression • PIK3CA overexpression • MSH6 expression
2d
Circular RNA circPFKP suppresses the proliferation and metastasis of gastric cancer cell via sponging miR-644 and regulating ADAMTSL5 expression. (PubMed, Bioengineered)
In conclusion, the circPFKP/miR-644/ADAMTSL5 regulatory pathway inhibited the malignant progression of GC. These findings may extend our understanding of the effects of circRNAs on cancer development and provide novel targets for the diagnosis of GC.
Journal
|
ADAMTSL5 (ADAMTS Like 5)
2d
Gnetum montanum extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells. (PubMed, Pharm Biol)
Forty-two compounds were identified from the GME. GME has a significant antitumor effect on colon cancer cells SW480, and it has the potential to be developed as an anticancer agent.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BAX expression
2d
Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV. (PubMed, PLoS One)
Knowledge of risk factors can help identify WLHIV at greatest risk of anal HPV 16 infection and, potentially, developing subsequent anal cancer. Identification of the subgroup of these women in whom HPV 16 persists could be an early step in the algorithm of anal cancer screening.
Journal
|
CD4 (CD4 Molecule)
2d
Pan-TRK Immunohistochemistry and NTRK Gene Fusions in Primary Carcinomas of the Liver. (PubMed, Appl Immunohistochem Mol Morphol)
IHC on TMA for TRK expression yields high false positive results, which should be validated on whole sections and confirmed by molecular genetic studies such as RNA sequencing. Many fusions involving genes other than NTRK are detected in HCC, the significance of which warrants further studies.
Journal
|
NTRK (Neurotrophic receptor tyrosine kinase) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
NTRK fusion
2d
Prognosis prediction of stage IV colorectal cancer patients by mRNA transcriptional profile. (PubMed, Cancer Med)
A panel of eight genes with significant mRNA level alterations was capable of predicting the prognosis and risk of the specific patient group. Future prospective study is needed to validate the model.
Journal
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • SMAD4 (SMAD family member 4) • TTN (Titin) • SAA2 (Serum Amyloid A2) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • NEUROD1 (Neuronal Differentiation 1)
|
TP53 mutation • KRAS mutation • PIK3CA mutation
2d
Colon Tumors in Enterotoxigenic Bacteroides fragilis (ETBF)-Colonized Mice Do Not Display a Unique Mutational Signature but Instead Possess Host-Dependent Alterations in the APC Gene. (PubMed, Microbiol Spectr)
Additionally, we performed whole-genome sequencing of human colon organoids exposed to ETBF to validate the mutational patterns seen in our mouse models and begin to understand their relevance in human colon epithelial cells. The results of this study highlight the importance of ETBF colonization in the development of sporadic CRC and in individuals with hereditary tumor conditions, such as Lynch syndrome and familial adenomatous polyposis (FAP).
Preclinical • Journal
|
APC (APC Regulator Of WNT Signaling Pathway)
|
APC mutation
2d
Long intergenic non-protein-coding RNA 467 promotes tumor progression and angiogenesis via the microRNA-128-3p/vascular endothelial growth factor C axis in colorectal cancer. (PubMed, Bioengineered)
Altogether, our results showed that LINC00467 contributes to CRC progression and angiogenesis via the miR-128-3p/VEGFC axis. Our findings expand the understanding of the mechanisms underlying CRC and suggest potential targets for clinical strategies against CRC.
Journal
|
BCYRN1 (Brain Cytoplasmic RNA 1) • VEGFC (Vascular Endothelial Growth Factor C) • MIR128 (MicroRNA 128)
2d
Identification of miR-195-5p as a novel prognostic biomarker for colorectal cancer. (PubMed, Mol Biol Rep)
In conclusion, the finding proposes that miR-195-5p might be a valuable biomarker and a prognostic factor for CRC in the future.
Journal
|
MIR195 (MicroRNA 195)
2d
A Deep Learning Model Based on MRI and Clinical Factors Facilitates Noninvasive Evaluation of KRAS Mutation in Rectal Cancer. (PubMed, J Magn Reson Imaging)
The proposed combined DL model incorporating T2WI and clinical factors may show good diagnostic performance. Thus, it could potentially serve as a supplementary approach for noninvasively evaluating KRAS mutation in rectal cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
KRAS mutation
2d
Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety. (PubMed, Cardiovasc Intervent Radiol)
DEB-TACE with CBs is a safe and well-tolerated therapy in patients with unresectable ICC with a low incidence of adverse events and relatively prolonged survival. Combined therapy and low CA125 are prognostic factors associated with longer survival.
Journal
|
MUC16 (Mucin 16, Cell Surface Associated)
|
Nexavar (sorafenib) • irinotecan
2d
CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer. (PubMed, Mol Cell Biochem)
Finally, MK promoted tumor growth and DDP resistance in a mice model bearing the SGC-7901/DDP xenografts. CAF-derived MK promotes EMT-mediated DDP resistance via upregulation of ST7-AS1 and activation of PI3K/AKT pathway.
Journal
|
ANXA5 (Annexin A5)
|
cisplatin
2d
IPO7 promotes pancreatic cancer progression via regulating ERBB pathway. (PubMed, Clinics (Sao Paulo))
IPO7 can act as an oncogenic factor and accelerate PC progression by modulating the ERBB pathway.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
2d
Hexavalent chromium triggers hepatocytes premature senescence via the GATA4/NF-κB signaling pathway mediated by the DNA damage response. (PubMed, Ecotoxicol Environ Saf)
In contrast to the classical senescence pathway p53-p21 and Rb/p16, GATA4 can directly regulate the secretion of SASP during premature senescence. The results will provide valuable clues for targeted prevention and further individualized treatment of Cr(VI)-associated cancers.
Journal
|
ATM (ATM serine/threonine kinase) • ATR (Ataxia telangiectasia and Rad3-related protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
2d
Induction of FGFR4 by H. pylori via STAT3 with a feedforward activation loop involving SRC signaling in gastric cancer. (PubMed, Gastroenterology)
Our findings demonstrated a link between infection, inflammation and FGFR4 activation where a feedforward activation loop between FGFR4 and STAT3 is established via SRC in response to H. pylori infection. Given the relevance of FGFR4 to the etiology and biology of gastric cancer, we propose FGFR4 as a druggable molecular vulnerability that can be tested in gastric cancer patients.
Journal
|
FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • STAT3 (Signal Transducer And Activator Of Transcription 3)
2d
LukS-PV inhibits the proliferation of hepatocellular carcinoma cells by maintaining FOXO3 stability via the PI3K/AKT signaling pathway. (PubMed, Cell Signal)
The protein synthesis inhibitor cycloheximide and the proteosome inhibitor MG132 were used to explore the potential mechanisms by which LukS-PV regulated FOXO3...Taken together, our data indicated that LukS-PV exert anticancer activities through FOXO3. LukS-PV may be a promising candidate for HCC treatment.
Journal
|
FOXO3 (Forkhead box O3)
|
MG132
2d
Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes. (PubMed, J Immunol)
Furthermore, similar cell clusters composed of HA-producing fibroblast-like cells and PD-L1 macrophages were detected in tumor-draining, but not in distant, lymph nodes. Collectively, our findings indicate that the formation of multiple large HA-enriched stromal clusters that support the development of PD-L1-expressing APCs in the tumor microenvironment and draining lymph nodes could contribute to the immune escape and resistance to immunotherapy in cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • VIM (Vimentin)
|
PD-L1 expression
2d
CA 209-678: Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=40, Active, not recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab)
2d
Trial completion • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
2d
A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations (clinicaltrials.gov)
P1; Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> May 2024
Trial completion date • Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation
|
BRACAnalysis CDx™
|
carmustine • melphalan • hydroxocobalamin (vit B12)
2d
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) (clinicaltrials.gov)
P1/2, N=14, Recruiting, University of Saskatchewan | Trial completion date: Aug 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR positive
|
TheraCIM (nimotuzumab)
2d
AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=542, Recruiting, BeiGene | Trial completion date: Aug 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> May 2024
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • capecitabine • albumin-bound paclitaxel • etoposide IV • pemetrexed • Baize’an (tislelizumab) • ociperlimab (BGB-A1217)
3d
FCRC22: Effect of FMD on Colorectal Cancer Patients (clinicaltrials.gov)
P=N/A, N=602, Not yet recruiting, Fudan University
New trial
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IGF1 (Insulin-like growth factor 1) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
3d
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PI3K (Phosphoinositide 3-kinases)
|
ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative
|
docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)
3d
Pancreas Registry and High Risk Registry (clinicaltrials.gov)
P=N/A, N=1200, Recruiting, Icahn School of Medicine at Mount Sinai | N=500 --> 1200 | Trial completion date: Feb 2022 --> Jun 2023 | Trial primary completion date: Feb 2022 --> Jun 2023
Enrollment change • Trial completion date • Trial primary completion date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MSH2 (MutS Homolog 2)
|
ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation
3d
KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1b, N=190, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2024 --> Jun 2023 | Trial primary completion date: Apr 2024 --> Jun 2023
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression • EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
3d
Comparison of Perioperative Outcomes Between Energy Device During Laparoscopic Gastrectomy (clinicaltrials.gov)
P=N/A, N=200, Recruiting, Seoul National University Hospital | Trial completion date: Jul 2021 --> Sep 2022
Trial completion date
|
IL6 (Interleukin 6) • IL10 (Interleukin 10)
3d
Immune Checkpoints, Immune Cells, and MHC Expression in the Tumor Microenvironment of Resected Hepatocellular Carcinomas (ATC 2022)
Significantly higher expression of CD4+, FoxP3-Treg, IC-PD-L1, MHC-I and HLA-G was observed in tumoral versus peritumoral samples. In contrast, NK-CD56 expression was higher in the peritumoral tissues. The strongest correlation between tumoral biomarkers was CD8+ with CD4+, FoxP3-Treg with IC-PD-L1 and IC-PD-1, and IC-PD-1 with IC-PD-L1.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)
|
CD8 expression • NCAM1 expression • CD4 expression • FOXP3 expression
3d
The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients (ATC 2022)
Radioembolization induces lymphopenia and further exacerbates T cells counts in lymphopenic patients. Sustained response to Y90 may account for increased senescent T cells in periphery. However, treatment-induced loss of effector T cells could impact ORR and PFS.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
3d
Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells (ATC 2022)
In conclusions, the administration of IL-2-stimulated NK cells derived from both living and deceased donor liver allografts was safely applied and is, therefore, a potential novel adjuvant immune treatment after LT in HCC patients.
Clinical
|
IL2 (Interleukin 2)
3d
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence (ATC 2022)
Pre-LT immune dysfunction significantly increases the risk of cancer recurrence post-LT. This preliminary analysis suggests the LIFI score, a pre-transplant calculated laboratory biomarker, correlates with early cancer recurrence. This may help assess and stratify patients with malignancy prior to liver transplant.
IO biomarker
|
CCL11 (C-C Motif Chemokine Ligand 11) • CD27 • CD40 (CD40 Molecule) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • MMP3 (Matrix metallopeptidase 3)
3d
Nanococktail Based on Supramolecular Glyco-Assembly for Eradicating Tumors In Vivo. (PubMed, ACS Appl Mater Interfaces)
Here, a phototherapeutic nanococktail atovaquone/17-dimethylaminoethylamino-17-demethoxygeldanamycin/glyco-BODIPY (ADB) was developed to enhance photodynamic therapy (PDT) and photothermal therapy (PTT) via alleviation of hypoxia and thermal resistance that was constructed using supramolecular self-assembly of glyco-BODIPY (BODIPY-SS-LAC, BSL-1), hypoxia reliever atovaquone (ATO), and heat shock protein inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)...Moreover, ADB exhibited good biosafety, and tumor eradication in vivo. Hence, this as-developed phototherapeutic nanococktail overcomes the substantial obstacles encountered by phototherapy in tumor treatment and offers a promising approach for the eradication of tumors.
Preclinical • Journal
|
HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
atovaquone
3d
Photosensitization of pancreatic cancer cells by cationic alkyl-porphyrins in free form or engrafted into POPC liposomes: The relationship between delivery mode and mechanism of cell death. (PubMed, J Photochem Photobiol B)
By contrast, L-2d does not affect the KRAS-Nrf2-GPX4 axis and activates cell death mainly through apoptosis. Overall, our study demonstrates for the first time that cationic alkyl porphyrins, which have a IC ~ 23 nM, activate a dual mechanism of cell death, ferroptosis and apoptosis, where the predominant form depends on the delivery mode.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • GPX4 (Glutathione Peroxidase 4)
3d
Anticancer and biological properties of new axially disubstituted silicon phthalocyanines. (PubMed, Dalton Trans)
They exhibited toxicity and apoptotic effect on the DLD-1 cell line. The findings reveal that the compounds can be utilized for cancer therapy after further investigations.
Journal
|
ANXA5 (Annexin A5)
3d
Asperuloside inhibited epithelial-mesenchymal transition in colitis associated cancer via activation of vitamin D receptor. (PubMed, Phytomedicine)
Asperuloside might prevent CAC through inhibiting EMT development via regulation of VDR/Smad3 pathway.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
3d
Mutational landscape of normal epithelial cells in Lynch Syndrome patients. (PubMed, Nat Commun)
Phylogenetic trees of tumour crypts indicate that the most recent ancestor cell of each tumour is already MMR deficient and has experienced multiple cycles of clonal evolution. This study demonstrates the genomic stability of epithelial cells with heterozygous germline MMR gene mutations and highlights important differences in the pathogenesis of LS from other colorectal cancer predisposition syndromes.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
3d
The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors. (PubMed, Sci Rep)
Morphological analysis and immunostaining demonstrated no obvious differences in CD8 cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood (t ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12 • KRAS expression
|
KS-58
3d
KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1. (PubMed, Hum Cell)
Moreover, KAT2A/E2F1 promoted tumorigenic activity and lung metastases of CC cells in mice. Taken together, our findings demonstrate the substantial role of KAT2A in the modulation of post-translational modifications of E2F1 in CC, suggesting that knockdown of KAT2A may be a potential strategy for CC treatment.
Journal
|
E2F1 (E2F transcription factor 1)
3d
Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. (PubMed, Genome Med)
By integrating liver single cell, single nucleus, and bulk expression data from multiple cohorts we identified a proliferating cell-type (Prol) enriched in HCC tumors, associated with a decreased overall survival, and linked to TP53 and RB1 somatic mutations.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation
3d
NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis. (PubMed, Genes Environ)
This integrated computational and experimental investigation revealed some new aspects of the lncRNA NEAT1 as a potential prognostic biomarker for the breast cancer and gastric cancer samples. Further investigations about NEA1 and correlated mRNAs, lncRNAs, and microRNAs - specially the mentioned RNAs in this study - can lead the researchers to more clear information about the role of NEAT1 in the breast cancer and gastric cancer.
Journal
|
MIR612 (MicroRNA 612) • XIST (X Inactive Specific Transcript)
3d
Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis. (PubMed, J Pathol Transl Med)
In conclusion, type of biospecimen could affect the role of F. nucleatum as a biomarker associated with clinicopathological features and prognosis.
Retrospective data • Review • Journal
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1)
|
KRAS mutation • BRAF mutation
3d
LncRNA cancer susceptibility 20 regulates the metastasis of human gastric cancer cells via the miR-143-5p/MEMO1 molecular axis. (PubMed, World J Gastroenterol)
Our findings indicate that CASC20 serves as a tumor promoter by regulating metastasis in GC via the miR-143-5p/MEMO1 axis. CASC20 may be a potential therapeutic target for GC.
Journal
|
MIR143 (MicroRNA 143)
3d
Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma. (PubMed, Cancer Res Commun)
Moreover, NURR1 regulated expression of two major autophagic genes ATG7 and ATG12 which are also overexpressed in pancreatic tumors and like NURR1 are negative prognostic factors for patient survival. Thus, gemcitabine-induced cytoprotective autophagy is due to the NURR1 - ATG7/ATG12 axis and this can be targeted and disrupted by NURR1 antagonist C-DIM12 demonstrating the potential clinical applications for combination therapies with gemcitabine and NURR1 antagonists.
Journal
|
ATG12 (Autophagy Related 12) • ATG7 (Autophagy Related 7)
|
gemcitabine
3d
Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway. (PubMed, World J Gastrointest Oncol)
XHP inhibited HCC cell growth and migration by stimulating apoptosis via the downregulation of the PI3K/Akt/mTOR signalling pathway, followed by the activation of caspase-9 and caspase-3. Our findings clarified that the antitumour effects of XHP on HCC cells are mediated by the PI3K/Akt/mTOR signalling pathway, revealing that XHP may be a potential complementary therapy for HCC.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
3d
Berberine retarded the growth of gastric cancer xenograft tumors by targeting hepatocyte nuclear factor 4α. (PubMed, World J Gastrointest Oncol)
Berberine retarded the growth of MGC803 and SGC7901 xenograft model tumors, and the mechanism behind these anti-growth effects might be the downregulation of the expression of HNF4α-WNT5a/β-catenin signaling pathways both in tumor tissues and liver tissues of the xenograft models.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KDR (Kinase insert domain receptor) • WNT5A (Wnt Family Member 5A)
|
Herceptin (trastuzumab) • Cyramza (ramucirumab)
3d
Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model. (PubMed, World J Gastrointest Oncol)
The bi-specific T1-positive contrast-enhanced MRI probe (UAG) for HCC demonstrated increased specificity and sensitivity to diagnose early-stage HCC irrespective of tumor size and/or heterogeneity.
Preclinical • Journal • MRI
|
AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
3d
Role of sirtuins in esophageal cancer: Current status and future prospects. (PubMed, World J Gastrointest Oncol)
However, the role of sirtuins in EC remains unclear due to the limited number of reports concerning sirtuins in EC. We herein review the current findings and future prospects of sirtuins in EC.
Review • Journal
|
SIRT1 (Sirtuin 1)
3d
miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1. (PubMed, Open Med (Wars))
In conclusion, miR-455-5p enhanced 5-Fu sensitivity by targeting PIK3R1 and DEPDC1 in CRC. This study provides a novel role of miR-455-5p in CRC and restoring miR-455-5p might be a therapeutic strategy to enhance chemosensitivity to 5-Fu.
Journal
|
PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MIR455 (MicroRNA 455)
|
PIK3R1 overexpression
|
5-fluorouracil
3d
Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. (PubMed, World J Hepatol)
FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management.
Journal
|
FGF19 (Fibroblast growth factor 19) • AFP (Alpha-fetoprotein)
3d
Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. (PubMed, Cancer Drug Resist)
To solve this problem, several clinical trials, such as irinotecan plus cetuximab vs. cetuximab monotherapy, have been conducted. Another clinical trial on irinotecan plus guadecitabine, a DNA-methyltransferase inhibitor, has also been conducted.
Review • Journal
|
ABCG2 • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
Erbitux (cetuximab) • irinotecan • guadecitabine (SGI-110)
3d
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. (PubMed, Cancer Drug Resist)
Moreover, IS1 and IS4 potentiated the sensitivity to gemcitabine in both conventional 2D monolayer and 3D spheroid cultures, and these results might be explained by the statistically significant increase in hENT1 expression (P < 0.05 vs. untreated control cells), potentially reversing PDAC chemoresistance. These results support further studies on new SF3B1 inhibitors and the role of RON/hENT1 modulation to develop effective drug combinations against PDAC.
Journal
|
SF3B1 (Splicing Factor 3b Subunit 1) • SLC29A1 (Solute Carrier Family 29 Member 1)
|
SF3B1 mutation
|
gemcitabine
3d
Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. (PubMed, J Pharm Anal)
At well-tolerated doses of 0.5 and 1 mg/kg, (i.v., twice), the inhibition rates were 91.2% and 94.8%, respectively (P<0.01). The results of this study indicate that the F-HSA-LDP multi-functional bioconjugate might be effective for treating K-Ras mutant pancreatic cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
3d
GB7 acetate, a galbulimima alkaloid from Galbulimima belgraveana, possesses anticancer effects in colorectal cancer cells. (PubMed, J Pharm Anal)
GB7 acetate was shown to have anti-proliferative, pro-autophagic, anti-metastatic, and anti-metabolite capabilities in HCT 116 cells. This study might provide new insights into cancer treatment efficacy and cancer chemoprevention.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
CDH1 expression
3d
Emerging actionable targets to treat therapy-resistant colorectal cancers. (PubMed, Cancer Drug Resist)
For example, overexpression and/or hyperactivation and/or amplification of oncogenic kinases can sustain resistance to targeted therapy whereas the composition of the gut microbiota, as well as that of the tumoral niche, and defects in DNA repair systems are crucial for determining the response to immunotherapy. In this review we will make an overview of the main resistance mechanisms identified so far and of the new therapeutic approaches to overcome it.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
3d
PWWP2B promotes DNA end resection and homologous recombination. (PubMed, EMBO Rep)
Taken together, our data show that PWWP2B facilitates the recruitment of DNA repair machinery to sites of DNA damage and promotes HR-mediated DNA double-strand break repair. Impaired PWWP2B function might thus cause genome instability and promote gastric cancer development.
Journal
|
RAD51 (RAD51 Homolog A) • MRE11A (MRE11 homolog, double strand break repair nuclease) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2)
3d
Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy. (PubMed, Oncol Rep)
In conclusion, HTN was a poor prognostic factor in pancreatic cancer patients receiving NAT followed by surgery, and the present study suggests a close association between HTN and tumor hypoxia. Increased hypoxia after NAT may support the thesis for re‑engineering the hypoxia‑alleviating tumor microenvironment in NAT regimens for pancreatic cancer.
Retrospective data • Journal
|
CA9 (Carbonic anhydrase 9)
3d
Conditional medium of gastric cancer mesenchymal stem cells promotes PD-L1 expression in gastric cancer cells and tumor growth via upregulating VGLL4 (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
Knockdown of VGLL4 inhibited the effect of GCMSCs-CM in promoting tumor growth in mice and enhanced the anti-tumor immunity of PBMCs-NCG mice. Conclusion GCMSCs-CM promotes the expression of PD-L1 and tumor growth by upregulating VGLL4 in gastric cancer cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
|
PD-L1 expression
3d
The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. (PubMed, J Natl Cancer Inst)
We identified an appreciable frequency of immunotherapy biomarkers and targetable genes alterations in both PC and BTC, with notable frequencies in PC samples lacking KRAS mutations and children/adolescent and young adult (AYA) populations, that should encourage CGP testing.
Journal • Real-world evidence • Tumor Mutational Burden • BRCA Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CDK12 (Cyclin dependent kinase 12) • GATA6 (GATA Binding Protein 6)
|
KRAS mutation • TMB-H • HER-2 amplification • HER-2 mutation • FGFR2 mutation • FGFR2 rearrangement • BRAF amplification
3d
Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients: A meta-analysis. (PubMed, Medicine (Baltimore))
miR-21, miR-106, miR-421, and miR-223 have good diagnostic efficacy, especially miR-421, could be used as auxiliary diagnostic indicator for GC.
Retrospective data • Journal
|
MIR21 (MicroRNA 21) • MIR106A (MicroRNA 106a) • MIR223 (MicroRNA 223)
3d
Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: A distinct entity among pancreatic tumors. (PubMed, Histopathology)
ITPN is a distinct pancreatic neoplasm with specific clinicopathological and molecular characteristics. Its recognition is fundamental for its clinical/prognostic implications and for the enrichment of potential targets for precision oncology.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • SMAD4 (SMAD family member 4) • MUC1 (Mucin 1) • RNF43 (Ring Finger Protein 43) • GNAS (GNAS Complex Locus) • MUC2 • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)
|
PIK3CA mutation • FGFR2 mutation • FGFR2 fusion
3d
Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. (PubMed, Cancer Res)
However, MSH2-deficient GCs also displayed addiction to BAZ1B, a bromodomain-containing family member, and consequent synthetic lethality to bromodomain and extra-terminal motif (BET) inhibition. Our results reveal a role for MSH2 in GC epigenomic regulation and identify BET inhibition as a potential therapy in MSH2-deficient gastric malignancies.
Journal • Mismatch repair
|
MSI (Microsatellite instability) • MSH6 (MutS homolog 6) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • MSH2 (MutS Homolog 2)
|
MSH2 mutation
3d
Emerging role for thymic stromal lymphopoietin-responsive regulatory T cells in colorectal cancer progression in humans and mice. (PubMed, Sci Transl Med)
Therapeutic blockade of TSLP using TSLP-specific monoclonal antibodies effectively inhibited the progression of colorectal tumors in this mouse model. Collectively, these data suggest that TSLP controls the progression of colorectal cancer through regulation of tumor-specific T function and represents a potential therapeutic target that requires further investigation.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CRLF2 (Cytokine Receptor Like Factor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • MEF2C (Myocyte Enhancer Factor 2C) • TSLP (Thymic Stromal Lymphopoietin) • IL33 (Interleukin 33)
|
CTLA4 expression
3d
Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. (PubMed, JCO Precis Oncol)
Detailed analysis of breakpoints in MSI-associated KFs support a model in which inefficient repair and/or processing of microbiome-induced clustered 8-oxoguanine damage in MSI CRC contributes to the increased incidence of specific oncogenic fusions.
Journal
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
|
NTRK1 fusion
3d
ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway. (PubMed, Braz J Med Biol Res)
ITGBL1 overexpression inversed the effects of JDP2 up-regulation on cell function. Collectively, we concluded that ITGBL1 may be transcriptionally suppressed by JDP2 and promote PC progression through the TGF-β/Smad pathway, indicating that ITGBL1 may have therapeutic potential for the treatment of PC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • JDP2 (Jun Dimerization Protein 2) • MXI1 (MAX Interactor 1) • JUN (Jun proto-oncogene)
3d
Is the tumor-stroma ratio a prognostic factor in gallbladder cancer? (PubMed, Rev Assoc Med Bras (1992))
A low tumor-stroma ratio tended to be a poor prognostic factor in gallbladder cancer, although not to a statistically significant degree. This can be considered one of the preliminary studies, as further studies involving larger groups are needed.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
3d
Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review. (PubMed, Z Gastroenterol)
FALLPRäSENTATION: Hier stellen wir einen fortgeschrittenen ICC-Patienten vor, der eine radikale Entfernung und eine adjuvante Chemotherapie (Gemcitabin + Cisplatin) erhalten hat...Dann erhielt er eine palliative Operation, Strahlentherapie und systemische Chemotherapie (Tegafur+Oxaliplatin (SOX) und Nab-Paclitaxel+Gemcitabin (AG))...SCHLüSSELWöRTER: Die BRAF V600E Mutation ist bei ICC ziemlich selten, daher wird sie in der Klinik nicht routinemäßig untersucht. Allerdings kann Präzisionsmedizin durch die NGS-Technologie verwirklicht werden, sodass die Ärzte bei der Behandlung der auf Chemotherapie-refraktären ICC die personalisierten genomischen Informationen nutzen können.
Review • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
cisplatin • Zelboraf (vemurafenib) • gemcitabine • albumin-bound paclitaxel
3d
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. (PubMed, Gut)
We describe a comprehensive TME-based stratification of iCCA. Cross-species analysis establishes murine models that align closely to human iCCA for the preclinical testing of combination strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • BAP1 (BRCA1 Associated Protein 1)
|
KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • BAP1 mutation
|
BI-3406
3d
Safety Study of SEA-CD40 in Cancer Patients (clinicaltrials.gov)
P1, N=159, Active, not recruiting, Seagen Inc. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2022 --> Dec 2022
Trial completion date • Trial primary completion date
|
CD40 (CD40 Molecule)
|
Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • SEA-CD40
3d
PHITT: Paediatric Hepatic International Tumour Trial (clinicaltrials.gov)
P3, N=300, Recruiting, University of Birmingham | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
Trial completion date • Trial primary completion date
|
AFP (Alpha-fetoprotein)
|
cisplatin • carboplatin • Nexavar (sorafenib) • gemcitabine • doxorubicin hydrochloride • etoposide IV • irinotecan • vincristine
3d
Pre-Habilitation Exercise Intervention (clinicaltrials.gov)
P=N/A, N=83, Recruiting, University of Rochester | Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
IL6 (Interleukin 6) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
3d
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov)
P2, N=40, Recruiting, University of Kansas Medical Center | Trial primary completion date: Apr 2022 --> Apr 2023
Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
3d
Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=44, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Nov 2025 | Trial primary completion date: Jan 2025 --> Nov 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
MSH6 (MutS homolog 6) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2)
|
MSH6 expression
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine
4d
Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer (clinicaltrials.gov)
P=N/A, N=70, Recruiting, Emory University | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
CD68 (CD68 Molecule) • CRP (C-reactive protein)
4d
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=360, Recruiting, Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021
Enrollment open • Trial initiation date
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ROS1 positive • ROS1 fusion • NTRK fusion
|
XZP-5955
4d
New trial • Real-world evidence
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
KIT mutation
|
imatinib • Sutent (sunitinib) • Ayvakit (avapritinib)
4d
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
Tukysa (tucatinib)
4d
On the development of a neoantigen vaccine for the prevention of Lynch Syndrome. (PubMed, Int J Cancer)
Additionally, immunohistochemistry showed that tumor-adjacent tertiary lymphoid organs were a potentially significant source of CD8 lymphocytes. Altogether, our results indicate that there may be a protective effect to patients carrying LS mutations through the induction of a peptide-specific CTL response from the use of neoepitope vaccination.
Journal
|
CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1)
4d
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. (PubMed, Gastroenterology)
Together, these data suggest that stromal HIF2 is an essential component of PDAC pathobiology and is a druggable therapeutic target that could relieve tumor microenvironment immunosuppression and enhance immune responses in this disease.
Journal • IO biomarker
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
|
HIF1A expression
|
PT2399
4d
Mucin 5AC-mediated CD44/ITGB1 clustering mobilizes adipose-derived mesenchymal stem cells to modulate pancreatic cancer stromal heterogeneity. (PubMed, Gastroenterology)
MUC5AC, secreted during PC progression, enriches in adipose and enhances the mobilization of AD-MSCs. On recruitment to pancreatic tumors, AD-MSCs proliferate and contribute towards stromal heterogeneity.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CD44 • FN1 (Fibronectin 1) • RAC1 (Rac Family Small GTPase 1) • PDX1 (Pancreatic And Duodenal Homeobox 1) • MUC5AC (Mucin 5AC) • ITGB1 (Integrin Subunit Beta 1)
|
MUC5AC expression
4d
Sox9, Hopx, and survivin and tuft cell marker DCLK1 expression in normal canine intestine and in intestinal adenoma and adenocarcinoma. (PubMed, Vet Pathol)
For survivin, no differences were detectable. In conclusion, stem cell markers Sox9, Hopx, and survivin were detectable at the crypt base and the immunoreactivity of Sox9, DCLK1, survivin, and Hopx was increased in canine intestinal adenomas and adenocarcinomas compared with normal mucosa.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1)
|
BIRC5 expression
4d
Profile of patients with hepatocellular carcinoma: An experience from a tertiary care center in India. (PubMed, Indian J Gastroenterol)
HCC due to unknown cause/NAFLD appears to be overtaking hepatitis B as the commonest cause for HCC. Despite the advances in diagnostic methods and surveillance, most cases of HCC tend to be diagnosed at advanced stages.
Observational data • Journal
|
AFP (Alpha-fetoprotein)
4d
DNA methylation and miRNA expression in colon adenomas compared with matched normal colon mucosa and carcinomas. (PubMed, Int J Exp Pathol)
Thus the significant changes in LINE-1 methylation and microRNA expression in precancerous lesions support an early role for epigenetic changes in the carcinogenic process. Epigenetic characteristics in adenomas may provide potential diagnostic and prognostic therapeutic targets early in cancer development at the adenoma stage.
Journal • Epigenetic controller
|
KRAS (KRAS proto-oncogene GTPase) • MIR200A (MicroRNA 200a) • Let-7c (MicroRNA Let-7c)
|
KRAS mutation • miR-200-a expression
4d
Circ_0085315 promotes cell proliferation, invasion, and migration in colon cancer through miR-1200/MAP3K1 signaling pathway. (PubMed, Cell Cycle)
circRNA_0085315 increased the phosphorylation levels of JNK, p38, and ERK1/2 by stimulating MAP3K1 up-regulation caused by miR-1200 inhibition. In conclusion, circRNA_0085315 serves as a ceRNA and promotes CC progression through the activation of the MAPK signaling pathway mediated via the miR-1200/MAP3K1 axis, suggesting that circRNA_0085315 may be a promising diagnostic and therapeutic target for CC.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • CDH2 (Cadherin 2)
|
CDH1 expression
4d
Involvement of NF-κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats. (PubMed, J Biochem Mol Toxicol)
Taken together, PRU improves functions of the liver, and as such prevents HCC. PRU can be used together with chemopreventives for HCC.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • IL1B (Interleukin 1, beta) • PCNA (Proliferating cell nuclear antigen) • CAT (Catalase)
|
CCND1 expression • BAX expression
4d
The Importance of Periodical Screening for Primary Hyperparathyroidism in a Pituitary Tumor Cohort in Searching Patients with MEN1 and its Genetic Profile. (PubMed, Endocr Pract)
Our results show that periodic screening for pHPT in patients with PTs may be useful to detect MEN1 syndrome; thus, it is recommended in those patients with both findings a genetic analysis of MEN1 gene and an additional search of related tumors. By contrast, our data suggest that CDKN1B and AIP mutations do not seem to play a relevant role in the pathogenesis of MEN1.
Journal
|
CDKN1B (Cyclin dependent kinase inhibitor 1B) • MEN1 (Menin 1)
4d
HSP90 mediates IFNγ-induced adaptive resistance to anti-PD-1 immunotherapy. (PubMed, Cancer Res)
The effectiveness and safety of combinations of anti-PD-1 immunotherapy with iron chelation or pharmacological inhibitors of HSP90 or IDO1 was confirmed in xenograft, orthotopic, and transgenic mouse models of pancreatic cancer. These findings support the rationale for future clinical trials in which widely used immunotherapies are combined with additional molecules that intercept resistance by iron chelation, IDO1 inhibition, or HSP90 neutralization.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
IFNG expression
4d
Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line. (PubMed, J Biochem Mol Toxicol)
In conclusion, thymoquinone, plumbagin and juglone significantly inhibited cell growth and induced ROS-mediated apoptosis in PANC-1 cells. In addition, they could be potent antimetastatic agents due to their anti-migratory effect against PANC-1 human pancreatic cancer cells.
Preclinical • Journal
|
MMP9 (Matrix metallopeptidase 9)
4d
Long noncoding RNA LBX2-AS1 promotes colorectal cancer progression via binding with PTBP1 and stabilizing KAT2A expression. (PubMed, J Biochem Mol Toxicol)
The KAT2A messenger RNA (mRNA) stability was probed using the transcriptional inhibitor Actinomycin D. LBX2-AS1 was significantly increased in CRC tissues and cells...LBX2-AS1 enhanced the mRNA stability of the histone acetyltransferase KAT2A by interacting with RNA-binding protein PTBP1. LBX2-AS1 acted as an oncogene in CRC.
Journal
|
PTBP1 (Polypyrimidine Tract Binding Protein 1)
|
dactinomycin
4d
Transcriptomic profiling of MSI-H/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy. (PubMed, Clin Cancer Res)
Several transcriptomic features, including CMS classification and related genes, were associated with response to PD-1 blockade in MSI-H/dMMR GI tumors. These findings can help develop predictive biomarkers or combination immunotherapies.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • IFNG (Interferon, gamma) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1)
|
MSI-H/dMMR • VEGFA overexpression • VEGFA expression
4d
RNA helicase DHX37 facilitates liver cancer progression by cooperating with PLRG1 to drive super enhancer-mediated transcription of cyclin D1. (PubMed, Cancer Res)
Importantly, CCND1 inhibitors were effective as antiproliferative agents for liver cancer. These results together demonstrate a cooperative mechanistic interaction between DHX37 and PLRG1 that regulates CCND1 expression and promotes liver cancer progression, advancing our understanding of the epigenetic and transcriptional dysregulations mediated by RNA helicases and super enhancers in HCC.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 expression
4d
Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer. (PubMed, Invest New Drugs)
An ultrafine iron oxide nanoparticle (uIONP) was used to encapsulate 7-ethyl-10-hydroxyl camptothecin (SN38), the water-insoluble active metabolite of pancreatic cancer chemotherapy drug irinotecan...The IGF1-uIONP/SN38 exhibited specific receptor-mediated cell targeting and cytotoxicity Ato MiaPaCa-2 and Panc02 pancreatic cancer cells with IC50 of 11.8 ± 2.3 and 20.8 ± 3.5 nM, respectively, but not to HEK293 human embryonic kidney cells. IGF1-uIONP significantly improved the targeted SN38 delivery to pancreatic cancer cells, holding the potential for in vivo theranostic applications.
Journal
|
IGF1 (Insulin-like growth factor 1)
|
irinotecan
4d
Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy. (PubMed, J Clin Lab Anal)
The results suggest that IINS may be an independent prognostic indicator for HCC patients treated with anti-PD-1 therapy. IINS-CA19-9 classification may be more effective in predicting clinical benefit of anti-PD-1 therapy in HCC patients.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
CA 19-9 (Cancer antigen 19-9) • CRP (C-reactive protein)
4d
Quantile-specific heritability of serum growth factor concentrations. (PubMed, Growth Factors)
Heritabilities of VEGF, HGF, angiopoitein-2, sTie-2 and sFlt-1 concentrations are quantile dependent. This may explain reported interactions of genetic loci (rs10738760, rs9472159, rs833061, rs3025039, rs2280789, rs1570360, rs2010963) with metabolic syndrome, diet, recurrent miscarriage, hepatocellular carcinoma, erysipelas, diabetic retinopathy, and bevacizumab treatment in their effect on VEGF concentrations.
Journal
|
HGF (Hepatocyte growth factor) • FLT1 (Fms-related tyrosine kinase 1)
|
Avastin (bevacizumab)
4d
Bcl-xL enforces a slow-cycling state necessary for survival in the nutrient-deprived microenvironment of pancreatic cancer. (PubMed, Cancer Res)
Bcl-xL expression was strongly associated with poor patient survival despite being confined to the slow-cycling fraction of human pancreatic cancer cells. These findings provide a rationale for combining traditional cancer therapies that target rapidly cycling cells with those that target quiescent, chemoresistant cells associated with nutrient and oxygen deprivation.
Journal
|
BCL2L1 (BCL2-like 1)
4d
A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer. (PubMed, J Clin Lab Anal)
The dual-marker panel consisting of CA199 and CTC number can significantly improve upon the diagnostic performance of CA199 alone, highlighting the promising clinical utilization as an effective strategy for PDAC surveillance.
Journal • Circulating Tumor Cells
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CA 19-9 (Cancer antigen 19-9)
4d
TULP3 silencing suppresses cell proliferation, migration and invasion in gastric cancer via the PTEN/Akt/Snail pathway. (PubMed, Cancer Treat Res Commun)
Our results reveal that TULP3 might serve as a potential prognostic biomarker and therapeutic target for the treatment of gastric cancer.
Journal
|
PTEN (Phosphatase and tensin homolog)
4d
Low clarithromycin resistance in virulent Helicobacter pylori from dyspeptic patients at a tertiary care centre in Odisha. (PubMed, Indian J Med Microbiol)
This is the first study that explored the antibiotic resistance of HP, and its virulence factors in dyspeptic patients from this region of India.
Journal
|
VCAM1 (Vascular Cell Adhesion Molecule 1)
|
amoxicillin • clarithromycin • levofloxacin
4d
Role of endoplasmic reticulum stress in apoptosis induced by HK2 inhibitor and its potential as a new drug combination strategy. (PubMed, Cell Stress Chaperones)
Endoplasmic reticulum stress plays a protective role in cell death induced by 3-BP. This result suggested that targeting HK2 and endoplasmic reticulum stress may be a valuable strategy in targeted and combination therapy of colon cancer.
Journal
|
HK2 (Hexokinase 2)
4d
Evaluation of genetic variants in nucleosome remodeling and deacetylase (NuRD) complex subunits encoding genes and gastric cancer susceptibility. (PubMed, Arch Toxicol)
Furthermore, we found that patients with higher CHD4 or GATAD2A mRNA expression level had more advantageous overall survival. Our findings indicated that genetic variants in NuRD complex subunits encoding genes may be promising predictors of gastric cancer risk.
Journal
|
CHD4 (Chromodomain Helicase DNA Binding Protein 4)
4d
Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism. (PubMed, Free Radic Biol Med)
Mechanistically, SLC7A11-AS1 directly suppressed xCT expression, while miR-33a-5p remarkably reduced SLC7A11-AS1 and xCT expression by directly targeting the SLC7A11-AS1 and xCT 3'UTRs. In addition, we found that low SLC7A11-AS1 expression activated the p38MAPK-JNK signaling pathway, and increased the expression of cisplatin export gene ATP7A and the GSH biosynthesis gene GCLM in GC.
Journal
|
SLC7A11 (Solute Carrier Family 7 Member 11)
|
SLC7A11 expression
|
cisplatin
4d
Hsa_circ_0060927 participates in the regulation of Caudatin on colorectal cancer malignant progression by sponging miR-421/miR-195-5p. (PubMed, J Clin Lab Anal)
Caudatin inhibited CRC cell malignancy through the hsa_circ_0060927/miR-421/miR-195-5p pathway, which provided a potential therapeutic agent for CRC.
Journal
|
MIR195 (MicroRNA 195)
4d
Inhibition of the Akt/NF-κB pathway is involved in the anti-gastritis effects of an ethanolic extract of the rhizome of atractylodes macrocephala. (PubMed, J Ethnopharmacol)
Our study illustrates that Am-EE suppresses the Akt/IκBα/NF-κB pathway and exerts an anti-inflammatory effect. These novel conclusions provide a pharmacological basis for the clinical use of the A. macrocephala rhizome in the treatment and prevention of gastritis and gastric cancer.
Journal
|
NFKBIA (NFKB Inhibitor Alpha 2)
|
ranitidine hydrochloride
4d
Hepatic Adenomas in Patients 60 and Older Are Enriched forHNF1AInactivation and Malignant Transformation. (PubMed, Am J Surg Pathol)
In conclusion, hepatic adenomas in persons 60 years of age or older are enriched forHNF1A-inactivated adenomas and have a higher frequency of malignant transformation. Malignant transformation, however, is less likely to develop through activation of the beta-catenin pathway.
Journal
|
HNF1A (HNF1 Homeobox A)
4d
A multicenter study on the preoperative prediction of gastric cancer microsatellite instability status based on computed tomography radiomics. (PubMed, Abdom Radiol (NY))
Radiomics markers based on CT images and clinical characteristics have the potential to be a non-invasive auxiliary diagnostic tool for preoperative assessment of gastric cancer MSI status, and they can aid in clinical decision-making and improve patient outcomes.
Clinical • Journal • Microsatellite instability • MSi-H Biomarker
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
4d
LINC00665 interacts with BACH1 to activate Wnt1 and mediates the M2 polarization of tumor-associated macrophages in GC. (PubMed, Mol Immunol)
In addition, genetic Wnt1 overexpression effectively abolished the repression of Wnt signaling after BACH1 depletion and mediated GC development by supporting M2 macrophage polarization. In conclusion, we report that LINC00665 modulates M2 macrophage polarization and suggest that it may facilitate macrophage-dependent GC progression.
Journal
|
BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • BACH1 (BTB Domain And CNC Homolog 1) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665)
4d
Advances in tests for colorectal cancer screening and diagnosis. (PubMed, Expert Rev Mol Diagn)
Many of the fecal biomarkers, from host cells or the gut environment, show better diagnostic sensitivity than FIT. New screening tests based on these fecal biomarkers can be expected to replace FIT with higher cost-effectiveness in the near future.
Journal
|
SEPTIN9 (Septin 9)
4d
Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. (PubMed, J Clin Lab Anal)
In summary, the DEGs and hub genes identified in the present study not only contribute to a better understanding of the molecular mechanisms underlying the carcinogenesis and progression of PDA but may also serve as potential new biomarkers and targets for PDA.
Journal
|
RAD51 (RAD51 Homolog A) • FN1 (Fibronectin 1) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • CEP55 (Centrosomal Protein 55)
4d
Prediction of the mechanism of Dachengqi Decoction treating colorectal cancer based on the analysis method of " into serum components -action target-key pathway". (PubMed, J Ethnopharmacol)
This study elucidated that most of the direct acting substances of DCQ in vivo were flavonoids and anthraquinones, which may play a role in regulating cell reproduction and apoptosis and inhibiting inflammation, providing a reference for the research of pharmacodynamic material basis and mechanism of DCQ in the treatment of CRC.
Journal
|
HRAS (Harvey rat sarcoma viral oncogene homolog) • IL6 (Interleukin 6) • MAPK1 (Mitogen-activated protein kinase 1) • IL17A (Interleukin 17A)
4d
Suppression of mutant Kirsten-RAS (KRAS)-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6. (PubMed, Oncogene)
Our data suggest that despite a common target in the ERK MAP kinase, DUSP5 and DUSP6 play partially non-redundant roles in suppressing oncogenic KRAS signalling, thus retarding both tumour initiation and progression. Our data suggest that loss of either DUSP5 or DUSP6, as observed in certain human tumours, including the pancreas, could promote carcinogenesis.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • DUSP6 (Dual specificity phosphatase 6)
|
KRAS mutation
4d
Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling. (PubMed, Oncogene)
Pharmacological blockages of SRC-1 and Hh signaling retarded CRC progression in human CRC cell xenograft mouse model. Together, our studies uncover an SRC-1/GLI2-regulated Hh signaling looping axis that promotes CRC tumorigenesis, offering an attractive strategy for CRC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • GLI2 (GLI Family Zinc Finger 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
BCL2 expression • CCND1 expression
4d
LncRNA TUG1 functions as a ceRNA for miR-1-3p to promote cell proliferation in hepatic carcinogenesis. (PubMed, J Clin Lab Anal)
LncRNA TUG1 can adsorb miR-1-3p as a competitive endogenous RNA (ceRNA) to promote the expression of IGF1 and promote cell proliferation in hepatic carcinogenesis.
Journal
|
IGF1 (Insulin-like growth factor 1)
4d
Knockdown of TRIM65 suppressed the proliferation and invasiveness of gastric cancer cells by restricting the ubiquitin degradation of PPM1A. (PubMed, Exp Cell Res)
In rescue experiments, suppression of PPM1A promoted the proliferation and invasion of gastric cancer cells transfected with sh-TRIM65. Therefore, our results suggested that knockdown of TRIM65 inhibited the proliferation and invasion of gastric cancer cells by suppressing the ubiquitin degradation of PPM1A and phosphorylation of TBK1.
Journal
|
PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A)
4d
Sensitive fluorescent detection of exosomal microRNA based on enzymes-assisted dual-signal amplification. (PubMed, Biosens Bioelectron)
Furthermore, patients with GC with or without metastases are discriminated using the proposed biosensor. Our technology may expand the applications of DNA-based biosensor-enabled cancer diagnostic tools.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MIR21 (MicroRNA 21)
4d
ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. (PubMed, J Cell Mol Med)
ASIC1a increased cell migration and invasion through EMT by regulating α and β-catenin, vimentin and fibronectin expression via the AKT/GSK-3β/Snail pathway driven by TGFβ/Smad signals. ASIC1a mediates drug resistance of HCC through EMT via the AKT/GSK-3β/Snail pathway.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FN1 (Fibronectin 1) • VIM (Vimentin)
|
VIM expression
4d
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. (PubMed, Oncogene)
In conclusion, SOX9 and FGF7 were prognostic biomarkers of CCA. WNT3A-TCF7-SOX9 axis could induce pemigatinib resistance in two independent pathways: (1)SOX9 directly promotes FGFR2 transcription and expression; (2)SOX9 elevates FGF7 expression, which could be secreted from CCA cells and activates FGFR2 phosphorylation in an autocrine pathway.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • SOX9 (SRY-Box Transcription Factor 9) • FGF7 (Fibroblast Growth Factor 7) • TCF7 (Transcription Factor 7)
|
FGFR2 overexpression • SOX9 expression
|
Pemazyre (pemigatinib)
4d
lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response. (PubMed, Int J Exp Pathol)
The inhibition of miR-411-5p reversed STAT3 and PD-L1 expression inhibited by MIAT knockdown in HCC cells. This study suggests a novel lncRNA-mediated mechanism for HCC cells to evade the immune response; MIAT/miR-411-5p/STAT3/PD-L1 may be a novel therapeutic target for HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • MIAT (Myocardial Infarction Associated Transcript)
|
PD-L1 expression
4d
Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway. (PubMed, J Cell Mol Med)
The upregulation of glycolysis in the HCC cells induced by sorafenib was impeded by NaBu, thereby enhancing the anti-HCC effect of sorafenib in vitro and in vivo. Thus, NaBu inhibits the expression of HK2 to downregulate aerobic glycolysis and the proliferation of HCC cells and induces their apoptosis via the c-myc pathway.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HK2 (Hexokinase 2)
|
MYC expression
|
Nexavar (sorafenib)
4d
Multi-omics joint analysis reveals the mechanism of action of the traditional Chinese medicine Marsdenia tenacissima (Roxb.) Moon in the treatment of hepatocellular carcinoma. (PubMed, J Ethnopharmacol)
For the first time, based on the theory that multiple components and multiple targets synergistically exert the beneficial effects of a traditional Chinese medicine, this paper comprehensively analyzes the mechanisms of action of M. tenacissima and provides a novel strategy for the subsequent development of anti-tumor therapies.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • JAK1 (Janus Kinase 1)
4d
Fusion HBx from HBV Integrant Affects Hepatocarcinogenesis through Deregulation of ER Stress Response. (PubMed, Virus Res)
Interestingly, the effects of fusion HBx on ER stress signaling pathway were similar to those of C-terminal truncated HBx, but significantly different from those of wild HBx. Our findings suggest that the fusion HBx plays a significant role in hepatocarcinogenesis by modifying ER stress response and could be an attractive target for the treatment of HBV-induced HCC.
Journal
|
ATF6 (Activating Transcription Factor 6) • ATF4 (Activating Transcription Factor 4)
4d
IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. (PubMed, Mol Immunol)
We also found that IL-6 activated two isoforms of STAT3 in Hep3B cells: STAT3α which contains both a DNA-binding domain and a transactivation domain and STAT3β which contains only the DNA-binding domain. Taken together, these findings raise the possibility that IL-6 not only induces CRP expression but also regulates the induction of CRP expression by activating STAT3 isoforms and by utilizing all four STAT3 sites.
Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
STAT3 mutation • IL6 expression
4d
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. (PubMed, Eur J Cancer)
Though in a limited retrospective series of patients, these results show the efficacy of the combination of anti-BRAF and anti-EGFRs in BRAFm mCRC patients previously treated with an anti-EGFR. The use of this combination should thus not be ruled out in this population with limited therapeutic options.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Tafinlar (dabrafenib) • Vectibix (panitumumab) • Braftovi (encorafenib)